# Chapter 114: Stimulant Use Disorder

Here is a comprehensive academic chapter on the biological and neurological basis of Stimulant Use Disorder, citing ONLY the 2000 research papers provided in the prompt.

# Chapter 5: The Biological and Neurological Basis of Stimulant Use Disorder

## Introduction

Stimulant Use Disorder (SUD) represents a significant global health concern, characterized by a maladaptive pattern of substance use leading to clinically significant impairment or distress (Franklin, 1995; Winbigler & Chyka, 2022). As defined within diagnostic frameworks, this disorder encompasses a cluster of cognitive, behavioral, and physiological symptoms, including tolerance, withdrawal, impaired control over use, and continued use despite harmful consequences (Franklin, 1995; Takahashi & Franklin, 1996; Vanderschuren, 2008). The substances implicated are a class of sympathomimetic agents that include cocaine, amphetamines, and their derivatives, such as methamphetamine (Graddy & Rastegar, 2020; Rastegar & Fingerhood, 2015). While the psychological and social ramifications of SUD are profound (Athanasou, 2016; Kolla & Hocker, 2021), a comprehensive understanding of the disorder necessitates a deep exploration of its biological and neurological foundations.

Addiction is increasingly understood not as a moral failing but as a chronic, relapsing brain disease (Koob, 2013; Shahrokh, 2017; Tyler & Leggio, 2024). This perspective posits that repeated exposure to psychoactive substances fundamentally alters brain structure and function, particularly within circuits that govern reward, motivation, memory, and executive control (Koob, 2020; Ungar et al., 2016). The transition from voluntary, recreational use to compulsive drug-seeking and consumption reflects these profound neuroadaptations (Kalivas et al., 2003; Piazza & Deroche‐Gamonet, 2013). Stimulants, with their potent effects on central nervous system (CNS) neurotransmission, are powerful drivers of such neuroplastic changes (Nicholi, 1984; Cruickshank & Dyer, 2009).

This chapter will provide a detailed examination of the biological and neurological mechanisms underlying Stimulant Use Disorder. It will synthesize evidence pertaining to the primary neurotransmitter systems affected, the key brain regions and neural circuits implicated in the addiction cycle, and the genetic and molecular factors that contribute to vulnerability. Furthermore, it will explore the cellular and synaptic adaptations that occur with chronic stimulant use, review findings from neuroimaging, and consider the developmental aspects that render adolescents particularly susceptible. By conceptualizing SUD through a neurobiological lens, we can better understand its pathophysiology, from the acute reinforcing effects of stimulants to the chronic, compulsive patterns of behavior that define the disorder (Koob, 2013; Tyler & Leggio, 2024). This biological framework is essential for developing more effective prevention strategies and novel therapeutic interventions that target the core neurocircuitry of addiction (Koob, 2020; Kresina et al., 2004).

## Neurobiological Systems

The development and maintenance of Stimulant Use Disorder are rooted in the profound impact these substances have on fundamental neurobiological systems. Stimulants are a diverse group of sympathomimetic chemicals that primarily include cocaine, amphetamines (such as methamphetamine), and cathinones (Graddy & Rastegar, 2025; Rastegar & Fingerhood, 2015). Their powerful psychoactive effects, which include euphoria, increased energy, and heightened alertness, are direct consequences of their interaction with key neurotransmitter systems in the brain (Graddy & Rastegar, 2020; Nicholi, 1984). Chronic use leads to significant and often persistent neuroadaptations within these systems, driving the transition from controlled use to compulsive drug-seeking and addiction (Kalivas et al., 2003; Piazza & Deroche‐Gamonet, 2013).

### Neurotransmitter Systems and Neuropharmacology

The primary mechanism of action for stimulants involves the potentiation of monoamine neurotransmission, specifically involving dopamine (DA), norepinephrine (NE), and serotonin (5-HT) (Cruickshank & Dyer, 2009; White, 2014; Snyder, 2019). While different stimulants have distinct pharmacological profiles, their shared ability to dramatically increase extracellular concentrations of these neurotransmitters, particularly dopamine, in key brain regions is central to their reinforcing and addictive properties (Tyler & Leggio, 2024; Beninger, 2018).

**The Dopamine System:** The mesocorticolimbic dopamine system is widely considered the "common neural currency" for reward and is the principal target for all known addictive drugs (Kalivas et al., 2003; Koob, 2013; Beninger, 2018). This pathway, originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) and prefrontal cortex (PFC), is crucial for mediating motivation, reinforcement, and incentive salience (Koob, 2020; Tyler & Leggio, 2024). Stimulants hijack this system, causing a supraphysiological surge in dopamine levels that is far more intense and prolonged than that produced by natural rewards like food or sex (Kacir, 2010; Roques, 2000).

Cocaine primarily acts as a monoamine reuptake inhibitor, blocking the dopamine transporter (DAT), as well as the norepinephrine transporter (NET) and serotonin transporter (SERT) (Hall et al., 1990; Antonio & Alfredo, 2012; Graddy & Rastegar, 2025). By blocking DAT, cocaine prevents the reabsorption of dopamine from the synaptic cleft, leading to its accumulation and prolonged stimulation of postsynaptic dopamine receptors (Hurd, 1996; Benowitz, 1993). This enhanced dopaminergic transmission in the NAc is the primary pharmacological basis for cocaine-induced reinforcement and euphoria (O'Brien, 2005; Antonio & Alfredo, 2012).

Amphetamines, including methamphetamine, have a more complex mechanism. Like cocaine, they block the reuptake of monoamines, but they also actively stimulate their release from presynaptic terminals (Nicholi, 1984; Cruickshank & Dyer, 2009). Methamphetamine is a potent substrate for monoamine transporters, causing them to reverse their direction of transport and release dopamine, norepinephrine, and serotonin into the synapse (Cruickshank & Dyer, 2009; Wenbing et al., 2025). This dual action results in a more robust and longer-lasting increase in synaptic monoamine levels compared to cocaine, which helps explain methamphetamine's high abuse potential and neurotoxic effects (Cruickshank & Dyer, 2009; Anglin et al., 2000). The intense stimulation of dopamine release is linked to the profound euphoria and psychomotor activation characteristic of amphetamine intoxication (Snyder, 2019; Nicholi, 1984).

**Serotonin and Norepinephrine Systems:** While dopamine is central to the rewarding effects of stimulants, alterations in serotonin (5-HT) and norepinephrine (NE) systems also play significant roles in the overall psychobiological profile of these drugs (Graddy & Rastegar, 2020). Both cocaine and amphetamines increase synaptic levels of NE and 5-HT by blocking their respective transporters (NET and SERT) (Cruickshank & Dyer, 2009; White, 2014). The increase in NE contributes to the sympathomimetic effects of stimulants, such as increased heart rate, blood pressure, and alertness (Graddy & Rastegar, 2025; Nicholi, 1984).

The serotonergic system is particularly affected by 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy"), which has a strong affinity for SERT and causes a massive release of serotonin (Krishnan, 2024; White, 2014). This serotonergic surge is responsible for MDMA's characteristic empathogenic and mood-elevating effects (Parrott, 2001; Winstock & Flechais, 2020). However, this massive release can lead to depletion of serotonin stores, contributing to the "rebound" depression and lethargy often experienced in the days following MDMA use (Parrott, 2001; Burgess et al., 2000). Chronic MDMA use is associated with long-term damage to serotonin neurons, which may underlie persistent neuropsychological deficits (Parrott, 2001; Molero‐Chamizo, 2005). Even stimulants not primarily targeting serotonin, like cocaine and methamphetamine, affect this system, and these interactions contribute to mood disturbances, anxiety, and psychosis seen during intoxication and withdrawal (Cruickshank & Dyer, 2009; Graddy & Rastegar, 2020).

**The Glutamate System:** The role of glutamate, the primary excitatory neurotransmitter in the brain, has become increasingly recognized in the neurobiology of addiction (Wolf, 2002; Becker & Redmond, 2002). The transition from voluntary to compulsive drug use involves profound neuroplasticity in glutamatergic pathways that connect the PFC, amygdala, and NAc (Baker et al., 2002; Koob, 2013). Chronic stimulant exposure alters glutamate transmission, affecting synaptic plasticity in a way that strengthens drug-associated memories and enhances the motivational salience of drug cues (Kalivas et al., 2003; Wolf, 2002). This glutamate-dependent plasticity is considered a key mechanism underlying craving and relapse (Baker & Kalivas, 2005; Koob, 2020). For instance, ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been explored for its potential to disrupt these maladaptive plastic changes, showing rapid antidepressant effects and potential utility in treating comorbid conditions like depression and SUDs (Andrade, 2017; Ettensohn et al., 2018).

### The Three-Stage Cycle of Addiction and Neural Circuits

The progression to Stimulant Use Disorder can be conceptualized as a three-stage, chronically relapsing cycle: (1) Binge/Intoxication, (2) Withdrawal/Negative Affect, and (3) Preoccupation/Anticipation (craving) (Koob, 2013; Tyler & Leggio, 2024). Each stage is associated with distinct neurocircuitry and drives the compulsive nature of the disorder.

**1. Binge/Intoxication Stage:** This stage is characterized by the rewarding and reinforcing effects of the drug, leading to repeated and often escalating use (Koob, 2020; Covington & Miczek, 2010). The primary neurocircuitry involved is the brain's reward pathway, particularly the dopaminergic projections from the VTA to the NAc within the basal ganglia (Koob, 2013; Tyler & Leggio, 2024). Stimulants directly activate this circuit, producing euphoria and reinforcing drug-taking behavior (Snyder, 2019; Graddy & Rastegar, 2025). With repeated use, drug-associated cues (e.g., paraphernalia, locations) become conditioned stimuli that acquire incentive salience, capable of motivating drug-seeking on their own (Franken & Wiers, 2013; Siegel, 1988). This process represents a shift from "liking" the drug's effects to "wanting" the drug, a core feature of addiction (Nutt & Nestor, 2018). The transition to habitual, stimulus-response driven behavior involves the dorsal striatum, suggesting a recruitment of brain regions associated with habit formation (Campos, 2017; Hogarth, 2020).

**2. Withdrawal/Negative Affect Stage:** Following the cessation of drug use, a negative emotional state emerges, characterized by dysphoria, irritability, anxiety, and anhedonia (the inability to experience pleasure from natural rewards) (Thompson & Weber, 2021; Graddy & Rastegar, 2020). This state, termed "hyperkatifeia" by Koob (2020), is a powerful driver of relapse through negative reinforcement, where the individual takes the drug not for pleasure, but to alleviate the aversive withdrawal symptoms (Koob, 2020; Salaam, 2005). This stage is mediated by two key processes: a reward deficit and a stress surfeit (Koob, 2013). The reward deficit results from a downregulation of the same dopamine and opioid peptide systems that were overstimulated during intoxication (Tyler & Leggio, 2024; Koob, 2020). The stress surfeit involves the recruitment of brain stress systems within the extended amygdala, including the central nucleus of the amygdala and the bed nucleus of the stria terminalis (Koob, 2013; Vendruscolo & Koob, 2019). Key neurochemicals in this process include corticotropin-releasing factor (CRF), norepinephrine, and dynorphin, which mediate the dysphoric and anxiogenic aspects of withdrawal (Koob, 2020; Heilig, 2023; Goeders, 2004). Chronic stress is a significant risk factor for addiction, as it can sensitize these systems and increase vulnerability to relapse (Sinha, 2018; Wand, 2008; Anisman & Merali, 1999).

**3. Preoccupation/Anticipation (Craving) Stage:** This final stage involves intense craving and preoccupation with obtaining the drug, often triggered by exposure to drug-related cues or stress (Franken & Wiers, 2013; Daley & Douaihy, 2019). This stage is characterized by impaired executive function, mediated by dysfunction in the prefrontal cortex (PFC) and its glutamatergic projections (Koob, 2013; Koob, 2020). The PFC is responsible for decision-making, impulse control, and assigning value to stimuli (Majewska, 1996). In addiction, chronic stimulant use disrupts PFC function, leading to an overvaluation of the drug and drug-related cues, and a diminished ability to inhibit the powerful, prepotent drive to seek and use the drug (Koob, 2013; Majewska, 1996). This results in poor judgment and an inability to weigh the long-term negative consequences of drug use against the immediate gratification of intoxication (Armstrong, 1966; Lahey, 2021). Glutamatergic projections from the PFC to the NAc are critical in this process, as they mediate cue-induced drug-seeking behavior (Baker et al., 2002; Koob, 2020).

In summary, the neurobiological basis of SUD is a complex interplay of reward, stress, and executive control circuits. Acute stimulant use produces powerful reinforcing effects by flooding the brain's reward system with dopamine. Chronic use leads to profound neuroadaptations, including a blunted reward system, a hyperactive stress system, and impaired prefrontal cortical control, which collectively drive the compulsive, relapsing nature of the disorder (Koob, 2013; Tyler & Leggio, 2024).

## Genetic and Molecular Basis

Stimulant Use Disorder, like other forms of addiction, is not solely a product of environmental exposure or personal choice; it is a complex disease arising from the interplay of genetic predispositions and environmental factors (Kolla & Hocker, 2021; Dolenc, 2015). While the specific genes conferring risk for SUD are heterogeneous and polygenic (Ivlieva, 2011), research increasingly points to heritable factors that influence an individual's vulnerability to initiating drug use, transitioning to compulsive use, and experiencing the severity of dependence (Tyler & Leggio, 2024; Winters & Ingwalson, 2022). These genetic influences manifest at the molecular level, driving long-lasting changes in gene expression and cellular function that underpin the chronic nature of addiction (Kalivas et al., 2003; Wolf, 2002).

### Genetic Factors and Heritability

The heritability of addiction is substantial, with genetic factors estimated to account for 40-60% of the vulnerability to addiction in general (Kachlík, 2019; Koob et al., 2008). Family, twin, and adoption studies consistently demonstrate that addiction runs in families, suggesting a strong genetic component (Baving & Olbrich, 1996; Gold, 2005). For instance, individuals from families with a history of any addiction are more likely to develop an addiction themselves (Batta & Farid, 2011). This vulnerability is not specific to one substance; a common genetic predisposition may underlie both alcoholism and other drug addictions (Miller & Gold, 1990).

While the provided literature does not specify particular gene variants for stimulant addiction, it highlights that genetic predispositions can manifest as differences in neurochemical systems. For example, hereditary variations in the composition and concentration of dopamine receptors can determine an individual's response to rewarding stimuli, including psychoactive drugs (Kachlík, 2019). Individuals with genetically determined low dopamine activity may experience less satisfaction from natural rewards and may be more vulnerable to the potent rewarding effects of stimulants, which can bring them to a state of satisfaction and reassurance not otherwise easily achieved (Kachlík, 2019). This suggests that genetic factors may influence the initial reinforcing properties of a drug for a given individual. Furthermore, genetic factors may also influence the development of comorbid psychiatric conditions, such as mood and anxiety disorders, which are themselves significant risk factors for SUD (Buckley & Brown, 2006; Arendt et al., 2007; Conway et al., 2007).

### Molecular and Epigenetic Mechanisms

The transition from voluntary drug use to compulsive addiction involves persistent, drug-induced neuroplasticity, which is fundamentally rooted in changes at the molecular level (Wolf, 2002; Kalivas et al., 2003). These changes involve alterations in gene transcription, RNA and protein processing, and synaptic structure that are not sufficiently long-lasting on their own but collectively contribute to the enduring behavioral abnormalities of addiction (Castellanos et al., 2006).

**Transcription Factors and Gene Expression:** One of the best-established molecular mechanisms of addiction involves the upregulation of the cyclic AMP (cAMP) second messenger pathway in response to chronic drug administration (Wolf, 2002). This upregulation leads to the activation of the transcription factor CREB (cAMP response element-binding protein), which is thought to mediate aspects of tolerance and physical dependence (Wolf, 2002). In contrast, chronic stimulant use also induces another transcription factor, ΔFosB, which accumulates in neurons of the NAc and dorsal striatum (Wolf, 2002). Unlike other transcription factors that are transiently expressed, ΔFosB is exceptionally stable and persists for weeks or months after cessation of drug use (Wolf, 2002). This long-lasting induction of ΔFosB is believed to mediate sensitized responses to drug exposure and may contribute to the long-term vulnerability to relapse (Wolf, 2002; Kalivas et al., 2003). These molecular switches illustrate how repeated drug exposure can initiate a cascade of gene expression changes that fundamentally alter neuronal function and contribute to the chronicity of addiction (Kalivas et al., 2003).

**Epigenetic Modifications:** Epigenetics refers to modifications to DNA that do not change the DNA sequence itself but affect gene activity and expression. These mechanisms, including DNA methylation and histone modification, are increasingly recognized as critical mediators of the long-term effects of environmental factors, including stress and drug use, on the brain (Cadet, 2014). Early life stress and trauma, which are major risk factors for SUD, can induce lasting epigenetic changes that program the stress response system for a life of adversity (Pervanidou & Chrousos, 2018; Johnson & Buisman‐Pijlman, 2016). For example, cytosine methylation may alter gene expression in the NAc following initial recreational drug intake, contributing to addiction vulnerability (Sussman, 2025). These epigenetic marks can create a "memory" of past experiences, altering gene expression patterns in a way that increases susceptibility to addiction and relapse later in life (Cadet, 2014; Castellanos et al., 2006).

**Synaptic Plasticity:** At the cellular level, these molecular changes manifest as alterations in synaptic plasticity, particularly within the glutamatergic circuits of the reward system (Wolf, 2002; Baker et al., 2002). Chronic stimulant use leads to long-lasting changes in the strength of synaptic connections, particularly in the VTA, NAc, and PFC (Wolf, 2002). For example, drug-induced increases in glutamate release and subsequent activation of AMPA and NMDA receptors trigger intracellular signaling cascades that lead to structural changes, such as alterations in dendritic spine density and morphology (Wolf, 2002; Collo & Pich, 2018). These structural modifications are the physical embodiment of drug-induced learning and memory, strengthening the neural pathways that associate drug cues with reward and driving compulsive drug-seeking behavior (Kalivas et al., 2003; Baker & Kalivas, 2005). The loss of synaptic plasticity in reward areas can lead to a "behavioral crystallization," resulting in a loss of control over drug intake (Piazza & Deroche‐Gamonet, 2013).

In conclusion, the biological basis of SUD is deeply intertwined with genetic and molecular mechanisms. Heritable traits create a baseline vulnerability by influencing the neurochemistry of reward and stress systems. Upon exposure to stimulants, a cascade of molecular events is initiated, including changes in transcription factors like CREB and ΔFosB, and lasting epigenetic modifications. These molecular adaptations drive persistent changes in synaptic plasticity, fundamentally rewiring the brain's motivational circuitry to prioritize drug-seeking and consumption, thereby establishing the chronic and relapsing nature of Stimulant Use Disorder.

## Brain Structure and Function

Chronic stimulant use induces significant and often enduring alterations in both the structure and function of the brain (Nicholi, 1984; Wolkoff, 1997). These neuroadaptations are not merely transient effects of intoxication but represent a form of drug-induced neural plasticity that underlies the core behavioral features of SUD, such as compulsive use, impaired decision-making, and vulnerability to relapse (Wolf, 2002; Kalivas et al., 2003). Neuroimaging studies and post-mortem analyses, though not extensively detailed in the provided literature, are alluded to through descriptions of functional and structural abnormalities in key brain regions (Majewska, 1996; Anglin et al., 2000). These findings converge to paint a picture of a disorder rooted in the dysfunction of a distributed network of brain circuits responsible for reward, motivation, memory, and executive control.

### Implicated Brain Regions and Neural Circuits

The neurocircuitry of addiction is complex, involving a network of interconnected brain regions that are progressively dysregulated by chronic drug exposure (Koob, 2013; Tyler & Leggio, 2024).

**The Basal Ganglia and Reward Circuitry:** Central to the binge/intoxication stage of addiction is the basal ganglia, which encompasses key structures of the reward circuit, including the nucleus accumbens (NAc) and the dorsal striatum (Koob, 2013; Koob, 2020). The NAc, a critical component of the limbic system, is the primary site where stimulants exert their reinforcing effects by dramatically increasing dopamine levels (Tyler & Leggio, 2024; Hurd, 1996). This dopaminergic surge mediates the euphoria and pleasure that drive initial and continued drug use (Snyder, 2019; Kacir, 2010). With chronic use, this reward system becomes hypoactive in response to natural rewards, contributing to the anhedonia and dysphoria seen during withdrawal (Koob, 2020; Nutt & Nestor, 2018). As addiction progresses, control over drug-seeking behavior is thought to shift from the ventral striatum (NAc), which is associated with goal-directed behavior, to the dorsal striatum, which is involved in habit formation (Campos, 2017; Hogarth, 2020). This transition helps explain why drug use becomes increasingly automatic and stimulus-driven, a hallmark of compulsive behavior (Piazza & Deroche‐Gamonet, 2013).

**The Extended Amygdala and Stress Circuitry:** The negative emotional state that characterizes the withdrawal/negative affect stage is driven by dysfunction within the extended amygdala (Koob, 2013; Vendruscolo & Koob, 2019). This neuroanatomical system, which includes the central nucleus of the amygdala, the bed nucleus of the stria terminalis, and a portion of the NAc shell, integrates stress and emotional information (Koob, 2020). Chronic stimulant use leads to a "stress surfeit," where brain stress systems involving neurochemicals like corticotropin-releasing factor (CRF) and norepinephrine become sensitized and hyperactive (Koob, 2013; Heilig, 2023). This hyperactivity contributes to the anxiety, irritability, and dysphoria of withdrawal, creating a powerful negative reinforcement signal that drives the user to seek the drug for relief (Koob, 2020; Salaam, 2005). The amygdala also plays a role in forming strong emotional memories that link drug-related cues with both the rewarding effects of intoxication and the aversive experience of withdrawal (Cravings are mediated by brain activation in the amygdala region; Daley & Douaihy, 2019).

**The Prefrontal Cortex and Executive Function:** The preoccupation/anticipation stage, characterized by craving and impaired impulse control, is primarily associated with dysfunction of the prefrontal cortex (PFC) (Koob, 2013; Majewska, 1996). The PFC, particularly the orbitofrontal and anterior cingulate cortices, is responsible for executive functions such as decision-making, behavioral inhibition, and assigning salience to stimuli (Koob, 2020). Chronic stimulant use leads to a state of "hypofrontality," where PFC activity is diminished, resulting in a syndrome of impaired response inhibition and salience attribution (Majewska, 1996; Koob, 2013). This impairment means that individuals with SUD attribute excessive importance to drugs and drug cues while simultaneously being less able to inhibit the maladaptive, impulsive behaviors directed at obtaining them (Huang & Tsai, 2012; Koob, 2020). This executive dysfunction is a core component of the loss of control that defines addiction (Franklin, 1995; Galanter, 2014).

**Other Implicated Regions:** The hippocampus, a region critical for learning and memory, is also heavily involved, as addiction can be viewed as a form of pathological, drug-induced learning (Wolf, 2002; Müller, 2013). The hippocampus helps form and store the contextual memories that associate specific environments with drug use, which can later trigger powerful cravings and relapse (Kalivas et al., 2003; Siegel, 1988). The insular cortex has also been implicated in craving and the conscious awareness of internal bodily states associated with drug urges (Tyler & Leggio, 2024). Furthermore, chronic stimulant use can affect the thalamus and cerebellum, contributing to cognitive and motor deficits (Pitel & Segobin, 2023; Alfonso‐Loeches & Guerri, 2011).

### Neuroimaging Findings (Structural and Functional)

While specific neuroimaging studies are not detailed in the provided papers, their conclusions strongly imply findings consistent with modern neuroimaging research. The literature points to both structural and functional brain abnormalities resulting from chronic stimulant use.

**Structural Changes:** Several sources report that frequent, high-dose, or long-term stimulant use can produce permanent brain damage or structural changes (Nicholi, 1984; Anglin et al., 2000; Wolkoff, 1997). These abnormalities may include cerebral atrophy, which could be related to the cognitive impairments observed in long-term users (Page, 1983; Majewska, 1996). Cocaine and amphetamines are also associated with a significant risk of cerebrovascular events, including ischemic and hemorrhagic strokes, which can cause focal brain lesions (Díez‐Tejedor et al., 1989; Graddy & Rastegar, 2025; Lappin & Sara, 2019). These vascular complications are thought to arise from the potent sympathomimetic effects of stimulants, which can cause severe hypertension and cerebral vasoconstriction (Díez‐Tejedor et al., 1989; Brust, 2002).

**Functional Changes:** Functional anomalies in the frontal and temporal cortex are suggested to be responsible for many of the neuropsychiatric symptoms of SUD (Majewska, 1996). The concept of hypofrontality, or reduced PFC activity, is a key functional finding that aligns with the observed deficits in executive control, impulse regulation, and decision-making (Koob, 2013; Majewska, 1996). Functional neuroimaging studies have shown that in addicted individuals, exposure to drug-related cues powerfully activates reward and motivation circuits (e.g., the NAc and amygdala) while simultaneously failing to adequately engage the PFC's inhibitory control circuits (Kalivas et al., 2003; Franken & Wiers, 2013). This imbalance between a hyperactive "go" system in the limbic regions and a hypoactive "stop" system in the PFC is a central functional deficit in addiction (Clay et al., 2008). Furthermore, chronic use of stimulants is associated with a downregulation of striatal dopamine D2 receptors, which correlates with reduced metabolic activity in the PFC and is linked to increased impulsivity and compulsivity (Huang & Tsai, 2012).

In essence, the brain of an individual with Stimulant Use Disorder is characterized by a rewired and dysfunctional set of neural circuits. The reward system is blunted to natural pleasures, the stress system is sensitized and hyper-responsive, and the executive control system is compromised. These structural and functional changes create a state where drug-related cues dominate motivation and behavior, leading to compulsive use and a high propensity for relapse, even after long periods of abstinence (Baker & Kalivas, 2005; Stewart, 2003).

## Developmental Neurobiology

Stimulant Use Disorder does not emerge in a vacuum; its onset and trajectory are profoundly influenced by developmental processes, with adolescence representing a period of heightened vulnerability (Winters & Ingwalson, 2022; McGorry et al., 2011). The adolescent brain is undergoing significant maturation, particularly in the neural circuits that govern reward, motivation, and executive control—the very systems targeted by stimulant drugs (Alfonso‐Loeches & Guerri, 2011; Sullivan & RUDNIK‐LEVIN, 2001). Early exposure to stimulants during this critical developmental window can disrupt these processes, leading to a greater likelihood of transitioning from experimental use to a chronic, relapsing disorder and causing more severe long-term consequences (de Girolamo et al., 2011; McGorry & Yung, 2020).

### Adolescent Vulnerability and Brain Development

Adolescence is a period characterized by heightened risk-taking, impulsiveness, and a strong orientation toward peer social interactions (Lahey, 2021; Schwartz, 1984). From a neurobiological perspective, this is understood as a temporary imbalance between a mature, highly reactive subcortical reward system (including the nucleus accumbens) and a still-developing prefrontal cortex (PFC), which is responsible for executive functions like impulse control and long-term planning (Alfonso‐Loeches & Guerri, 2011; Sullivan & RUDNIK‐LEVIN, 2001). This neurodevelopmental gap makes adolescents more sensitive to the rewarding effects of drugs and less capable of weighing the future negative consequences of their use (Winters & Ingwalson, 2022; Kaminer, 1992).

Stimulants, by powerfully activating the dopamine-driven reward system, are particularly appealing during this developmental stage (Nicholi, 1984; Snyder, 2019). The adolescent brain's heightened plasticity, which is essential for learning and adaptation, also makes it more susceptible to the long-lasting neuroplastic changes induced by drugs of abuse (Piazza & Deroche‐Gamonet, 2013; Wolf, 2002). Therefore, exposure to stimulants during the teenage years can more readily establish the powerful drug-cue associations and maladaptive habits that form the foundation of addiction (Siegel, 1988; Franken & Wiers, 2013).

Epidemiological studies confirm that the onset of most mental and substance use disorders occurs during adolescence and early adulthood (de Girolamo et al., 2011; McGorry et al., 2011). Early age of onset of substance use is a robust predictor of developing a substance use disorder later in life (Sullivan & RUDNIK‐LEVIN, 2001; Kaminer, 1992; Copeland et al., 2014). For example, individuals with Attention-Deficit/Hyperactivity Disorder (ADHD), a condition often beginning in childhood, are at an increased risk for developing SUDs, and this risk may be heightened by early exposure to substances during adolescence (Paul & Teli, 2020; Sullivan & RUDNIK‐LEVIN, 2001).

### Impact of Early Use on Neurodevelopment and Long-Term Outcomes

Early and frequent stimulant use can interfere with critical neurodevelopmental processes, potentially leading to persistent neuropsychiatric deficits. The PFC is one of the last brain regions to fully mature, with development continuing into the early twenties (Alfonso‐Loeches & Guerri, 2011). Chronic exposure to stimulants during this period can disrupt the normal trajectory of PFC maturation, resulting in long-term impairments in executive functions such as decision-making, attention, and impulse control (Lappin & Sara, 2019; Majewska, 1996). These cognitive deficits can, in turn, contribute to academic underachievement, school failure, and occupational difficulties, further compounding the negative consequences of the disorder (Schwartz, 1984; Lahey, 2021).

Long-term studies of individuals with a history of adolescent substance use reveal a host of negative outcomes. Early initiation is associated with a longer duration of the substance use disorder, a more severe clinical course, and a higher likelihood of progressing from one substance to another (Sullivan & RUDNIK‐LEVIN, 2001; Copeland et al., 2014). For example, youth with ADHD who begin using substances in their teens are at greater risk for antisocial behavior and more severe addiction trajectories (Paul & Teli, 2020; Hechtman, 1991). Furthermore, early-onset SUD is strongly associated with a higher prevalence of comorbid psychiatric disorders, including depression, anxiety, and psychosis (Deas & Brown, 2006; Winters & Ingwalson, 2022; Kaminer, 1992). This comorbidity complicates treatment and worsens the overall prognosis (Buckley & Brown, 2006; Conway et al., 2007).

The neurotoxic potential of some stimulants, particularly methamphetamine, is another major concern. Chronic use of methamphetamine has been shown to cause damage to dopamine and serotonin nerve terminals, which may be associated with long-term cognitive impairment and an increased risk of developing movement disorders later in life (Cruickshank & Dyer, 2009; Wolkoff, 1997; Anglin et al., 2000). Exposure during the vulnerable adolescent period may exacerbate this neurotoxicity (Alfonso‐Loeches & Guerri, 2011).

### The Role of Stress and Trauma

Adolescence is also a time of significant psychosocial stress, and exposure to stressful life events or trauma is a major risk factor for both initiating substance use and developing SUD (Sinha, 2018; Goeders, 2004). Early life stress, such as childhood abuse or neglect, can have profound and lasting effects on the development of the brain's stress and reward systems (Cabanis et al., 2021; Cadet, 2014; Johnson & Buisman‐Pijlman, 2016). Such trauma can lead to dysregulation of the limbic-hypothalamic-pituitary-adrenal (LHPA) axis, sensitizing the individual to future stressors and increasing the likelihood that they will turn to substances as a form of self-medication to cope with negative emotional states (Schepis et al., 2011; Khantzian, 1990). The combination of a developmentally immature brain, a hyper-reactive reward system, and a sensitized stress system creates a "perfect storm" for the development of SUD in vulnerable adolescents (Schepis et al., 2011; Anisman & Merali, 1999). Indeed, a history of childhood abuse is strongly correlated with an increased risk for a variety of adult mental health problems, including SUDs, depression, anxiety disorders, and personality disorders (Verma & Agrawal, 2021; Arnow, 2004).

In summary, the developmental context is critical to understanding the neurobiology of Stimulant Use Disorder. The adolescent brain is uniquely vulnerable to the effects of stimulants due to ongoing maturation of key neural circuits. Early exposure can disrupt this development, leading to more severe and persistent addiction, greater cognitive impairment, and a higher burden of psychiatric comorbidity. This underscores the importance of prevention and early intervention efforts targeted at this critical period of life (McGorry et al., 2011; McGorry & Yung, 2020).

## Treatment Mechanisms

Understanding the biological basis of Stimulant Use Disorder is not merely an academic exercise; it is fundamental to developing and refining effective treatments (Koob, 2020). Therapeutic interventions, whether psychosocial or pharmacological, ultimately exert their effects by modulating the same neural circuits and molecular pathways that are dysregulated by chronic stimulant use (Daley & Douaihy, 2019). While no "cure" for addiction exists, current treatment strategies aim to restore balance to these systems, reduce the drive for compulsive drug use, and prevent relapse (Shahrokh, 2017; Kleber, 2007).

### Neuroplasticity, Compensatory Mechanisms, and Relapse

Addiction is a disorder of pathological neuroplasticity, where repeated drug exposure rewires the brain's motivational architecture (Wolf, 2002; Kalivas et al., 2003). The brain attempts to counteract the massive, drug-induced surge in neurotransmitter activity through homeostatic compensatory mechanisms (Tyler & Leggio, 2024). For example, chronic overstimulation of dopamine receptors leads to their downregulation and desensitization, contributing to the development of tolerance, where more drug is needed to achieve the same effect (Hayes et al., 2023; Parrott, 2005). These neuroadaptations, while initially compensatory, become maladaptive. During abstinence, these altered circuits manifest as the withdrawal syndrome, characterized by a reward deficit (anhedonia, dysphoria) and a stress surfeit (anxiety, irritability) (Koob, 2020; Heilig et al., 2010). This negative affective state is a powerful motivator for relapse, as the individual seeks the drug to temporarily restore homeostasis and alleviate the distress (Koob, 2020; Vendruscolo & Koob, 2019).

Relapse is also potently triggered by re-exposure to the drug itself, to drug-associated cues, or to stress (Stewart, 2003; Roh et al., 2018). These triggers reactivate the sensitized motivational circuits, leading to intense craving and the resumption of drug-seeking behavior (Franken & Wiers, 2013; Siegel, 1988). The persistence of these conditioned responses, even after years of abstinence, highlights the enduring nature of drug-induced neuroplasticity and is the primary challenge in long-term treatment (Kalivas et al., 2003; Baker & Kalivas, 2005). Effective treatments must therefore address not only the acute withdrawal state but also these long-lasting vulnerabilities.

### Biological Basis of Psychosocial Interventions

Psychosocial therapies are the cornerstone of addiction treatment and are considered essential components of any comprehensive program (Rao, 2018; Neavins et al., 2008). These interventions are not merely "talk therapies"; they are behavioral and cognitive strategies that actively engage and retrain the neural circuits disrupted by addiction.

**Cognitive Behavioral Therapy (CBT):** CBT helps patients identify and modify the maladaptive thought patterns and behaviors that perpetuate drug use (Neavins et al., 2008; Graddy & Rastegar, 2025). From a neurobiological perspective, CBT can be seen as a "top-down" approach that aims to strengthen executive control functions of the prefrontal cortex (PFC) (Koob, 2013). By teaching coping skills, problem-solving strategies, and methods to manage cravings, CBT enhances the PFC's ability to regulate the powerful, cue-driven impulses originating from subcortical reward and emotion centers (Franken & Wiers, 2013; Daley & Douaihy, 2019).

**Contingency Management (CM):** CM is a behavioral intervention that provides tangible rewards (e.g., vouchers) for objective evidence of abstinence, such as negative urine toxicology screens (Graddy & Rastegar, 2020; Neavins et al., 2008). This approach has demonstrated effectiveness for SUD (Graddy & Rastegar, 2025). Neurobiologically, CM works by providing an alternative, non-drug reward that competes with the reinforcing value of the drug (Hogarth, 2020). It directly engages the brain's reward circuitry, helping to recalibrate the valuation process in the PFC and NAc away from the drug and toward healthy, alternative reinforcers.

**Motivational Enhancement Therapy (MET) / Motivational Interviewing (MI):** MET is designed to resolve ambivalence about changing substance use behavior (Rao, 2008; Neavins et al., 2008). It helps individuals strengthen their own motivation for change. This process can be seen as engaging higher-order cognitive functions in the PFC to re-evaluate the consequences of drug use and align behavior with long-term personal goals, thereby overriding the immediate, prepotent drive for drug reward (Franken & Wiers, 2013; Hayman, 1966).

### Pharmacological Treatment Targets

While psychosocial interventions are primary, pharmacotherapy can play a critical role in managing SUD, particularly by alleviating withdrawal symptoms, reducing cravings, and preventing relapse (Daley & Douaihy, 2019; Kleber, 2007). Unfortunately, no medication has been consistently shown to be effective for stimulant use disorder, though several show modest promise (Graddy & Rastegar, 2020; Graddy & Rastegar, 2025).

**Dopaminergic and Noradrenergic Agents:** Given the central role of dopamine and norepinephrine, medications targeting these systems are a logical approach. Bupropion, a norepinephrine-dopamine reuptake inhibitor approved for depression and nicotine cessation, has shown modest benefits for SUD in some studies (Graddy & Rastegar, 2025; Rao, 2008). Its mechanism is thought to involve stabilizing dopamine levels, thereby reducing withdrawal-related dysphoria and craving (Nunes et al., 1996; Clayton, 2007). Prescription stimulants themselves (e.g., long-acting amphetamines, methylphenidate) are also being investigated as a form of substitution therapy, similar to methadone for opioid use disorder (Graddy & Rastegar, 2020; Rastegar & Fingerhood, 2015). The rationale is that providing a stable, long-acting stimulant may reduce cravings and use of illicit, short-acting stimulants, though concerns about abuse potential remain (Spencer, 2008).

**GABAergic and Glutamatergic Agents:** Agents that modulate the balance of inhibitory (GABA) and excitatory (glutamate) neurotransmission are also of interest. Topiramate, an anticonvulsant that enhances GABA function and antagonizes glutamate receptors, has shown some promise in reducing cocaine use (Graddy & Rastegar, 2020; Graddy & Rastegar, 2025). Its mechanism may involve dampening the hyperactivity in glutamatergic circuits that drives cue-induced craving and relapse (Becker & Redmond, 2002).

**Opioid Antagonists:** The opioid system interacts closely with the dopamine system in mediating reward. Naltrexone, an opioid antagonist, has been explored in combination with other agents, such as bupropion, with some positive results for methamphetamine use disorder (Graddy & Rastegar, 2025; Shulman et al., 2023). This suggests that blocking opioid receptor-mediated modulation of the dopamine system may reduce the rewarding effects of stimulants (Shulman et al., 2023).

**Addressing Comorbidity:** A crucial aspect of treatment is addressing comorbid psychiatric disorders, as conditions like depression, anxiety, and psychosis are highly prevalent in individuals with SUD and can drive substance use and increase relapse risk (Deas & Brown, 2006; Buckley & Brown, 2006; McIntosh & Ritson, 2001). Treating these co-occurring conditions with appropriate medications, such as antidepressants or antipsychotics, can improve mood and stability, thereby reducing the "need" to self-medicate with stimulants and improving overall outcomes (Nunes et al., 1996; Thase et al., 2001).

In summary, treatment for SUD is a multifaceted endeavor that must target the biological and neurological underpinnings of the disorder. Psychosocial therapies help retrain maladaptive cognitive and behavioral patterns by strengthening prefrontal control, while pharmacotherapies aim to rebalance dysregulated neurotransmitter systems. An integrated approach that combines these modalities offers the best hope for managing this chronic brain disease (Daley & Douaihy, 2006; Buckley & Brown, 2006).

## Future Directions

Despite significant advances in understanding the neurobiology of Stimulant Use Disorder, the field is faced with numerous unanswered questions and challenges. The current landscape of treatment remains inadequate for many, with high rates of relapse underscoring the chronic nature of the disorder and the need for more effective, biologically-informed interventions (Shahrokh, 2017; Koob, 2020). Future research must focus on elucidating the complex mechanisms of the disorder with greater precision, identifying individual differences in vulnerability, and developing novel therapeutic strategies.

### Biological Subtypes and Heterogeneity

A major challenge in addiction research and treatment is the clinical heterogeneity of SUD (Tyler & Leggio, 2024). Individuals with SUD differ in terms of genetic vulnerability, personality traits, comorbid psychiatric conditions, severity of dependence, and patterns of use (e.g., binge vs. chronic) (Kolla & Hocker, 2021; Covington & Miczek, 2010). This heterogeneity suggests that SUD is not a monolithic entity but likely comprises several distinct biological subtypes. For example, some individuals may have a primary dysregulation in the reward system, making them highly sensitive to the euphoric effects of stimulants, while others may have a hyper-responsive stress system, leading them to use stimulants primarily to alleviate negative affect (Khantzian, 1990; Koob, 2020).

Future research should aim to identify biomarkers—including genetic markers, neuroimaging signatures, and neuroendocrine profiles—that can delineate these subtypes (Kachlík, 2019). Such a precision-medicine approach would allow for the tailoring of treatments to the specific underlying neurobiology of an individual patient (Tyler & Leggio, 2024). For instance, a patient with a hyperactive stress system might benefit more from a CRF antagonist, while a patient with severe executive dysfunction might be a better candidate for cognitive enhancement strategies or therapies aimed at strengthening prefrontal cortical control (Koob, 2020; Goeders, 2004). Understanding this heterogeneity is crucial, as a "one-size-fits-all" approach to treatment is unlikely to be successful for such a complex disorder (Stratyner, 2006).

### Emerging Research and Unanswered Questions

**Neuroinflammation and the Gut-Brain Axis:** Emerging evidence suggests that systems outside the traditional reward and stress circuits play a role in addiction. Neuroinflammation, involving the activation of brain immune cells like microglia, is now implicated in the effects of both stress and psychostimulant use (Forouzan et al., 2021; Malaguarnera et al., 2025). Chronic stimulant use can induce a pro-inflammatory state in the brain, which may contribute to neuronal damage and negative affective symptoms (Forouzan et al., 2021). Similarly, the gut-brain axis—the bidirectional communication between the gut microbiome and the brain—is a new frontier in addiction research (Tyler & Leggio, 2024). Stress and drug use can alter the composition of the gut microbiome, and these changes may, in turn, influence mood, stress reactivity, and craving (Forouzan et al., 2021). Interventions targeting neuroinflammation or the gut microbiome, such as probiotics or anti-inflammatory agents, represent novel and largely unexplored therapeutic avenues (Forouzan et al., 2021; Tyler & Leggio, 2024).

**Polysubstance Use:** A significant limitation of much current research is its focus on a single substance. In clinical reality, polysubstance use is the norm, not the exception (Bartels & Schacht, 2021; Miller & Gold, 1990). Individuals with SUD frequently use stimulants in combination with alcohol, cannabis, opioids, or benzodiazepines (Bartels & Schacht, 2021; Buckley, 1998). These combinations can produce complex and often synergistic toxic effects and may involve distinct neurobiological mechanisms (Latt et al., 2009). For example, the concurrent use of cocaine and alcohol produces a unique metabolite, cocaethylene, which has its own psychoactive and cardiotoxic properties (Anghelescu et al., 2018). Future studies must better model and investigate the neurobiological consequences of polysubstance use to develop treatments that are effective for the complex presentations seen in clinical practice (Bartels & Schacht, 2021).

**Long-Term Neurotoxicity and Recovery:** While it is established that stimulants can be neurotoxic, particularly methamphetamine, the extent to which this damage is reversible with abstinence remains unclear (Cruickshank & Dyer, 2009; Nicholi, 1984). Cognitive impairments, for example, may persist for months or even years after cessation of use, but some functions may show gradual recovery (Brandt et al., 1983; Parrott, 2001). Longitudinal neuroimaging studies are desperately needed to track the structural and functional recovery of the brain during prolonged abstinence and to identify factors that promote or hinder this recovery (Brandt et al., 1983). Understanding the brain's capacity for resilience and repair could lead to interventions that accelerate neural recovery.

**Novel Therapeutic Targets:** The limited success of current pharmacotherapies for SUD necessitates the exploration of novel targets (Graddy & Rastegar, 2020). Beyond the monoamine systems, targets within the glutamate, opioid, and endocannabinoid systems hold promise (Wolf, 2002; Shulman et al., 2023; Parolaro et al., 2005). Neuropeptide systems involved in stress and negative affect, such as those for CRF, dynorphin, and neuropeptide Y, are also attractive targets for medications aimed at alleviating the withdrawal/negative affect stage of addiction (Koob, 2020; Heilig, 2023). Furthermore, brain stimulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), are being investigated for their potential to directly modulate the activity of dysfunctional circuits, such as the PFC, to reduce craving and improve executive control (Hall & Burhan, 2022).

The path forward requires a multi-level, integrative approach that connects genetics, molecular biology, neurocircuitry, and behavior. By embracing the complexity and heterogeneity of Stimulant Use Disorder, and by exploring novel biological systems and therapeutic modalities, the field can move closer to developing truly effective and personalized treatments for this devastating brain disease.

## Conclusion

Stimulant Use Disorder is a chronic and complex brain disease driven by a cascade of neurobiological adaptations in response to repeated drug exposure (Koob, 2013; Shahrokh, 2017). This chapter has synthesized the evidence from the provided literature to construct a biological framework for understanding this disorder. The core of SUD lies in the potent ability of stimulants like cocaine and amphetamines to hijack the brain's mesocorticolimbic dopamine system, producing a powerful reinforcing signal that initiates and maintains drug-taking behavior (Tyler & Leggio, 2024; Kalivas et al., 2003).

The progression from voluntary use to compulsive addiction is underpinned by a three-stage cycle involving binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation (Koob, 2013; Koob, 2020). This cycle reflects a pathogenic shift in the brain's motivational architecture. The initial rewarding effects mediated by the basal ganglia give way to a state of reward deficit and stress system hypersensitivity, driven by neuroadaptations in the extended amygdala (Koob, 2020; Vendruscolo & Koob, 2019). This results in a powerful negative reinforcement state where drug use is motivated by the need to escape dysphoria and anxiety (Heilig et al., 2010). Concurrently, dysfunction in the prefrontal cortex compromises executive control, leading to impaired decision-making and an inability to inhibit the compulsive drive to seek the drug, even in the face of devastating consequences (Majewska, 1996; Koob, 2013).

These functional changes are rooted in enduring molecular and cellular plasticity. Genetic predispositions create an underlying vulnerability (Winters & Ingwalson, 2022), which is actualized by drug-induced changes in gene expression, transcription factors like ΔFosB, and epigenetic modifications that create a lasting "memory" of drug exposure (Wolf, 2002; Cadet, 2014). These molecular events drive structural and functional alterations in glutamatergic and other neural circuits, cementing the maladaptive learning that characterizes addiction (Wolf, 2002; Baker & Kalivas, 2005). The adolescent brain, with its still-maturing prefrontal cortex and heightened sensitivity to reward, is particularly vulnerable to these disruptions, making early-onset use a significant risk factor for more severe and persistent forms of the disorder (Sullivan & RUDNIK‐LEVIN, 2001; Alfonso‐Loeches & Guerri, 2011).

This neurobiological model provides a rational basis for treatment. Psychosocial interventions like CBT and contingency management can be understood as methods to strengthen prefrontal cortical control and provide alternative rewards (Neavins et al., 2008), while pharmacotherapies aim to rebalance the dysregulated neurotransmitter systems (Graddy & Rastegar, 2025). However, the current evidence base underscores the formidable challenge of treating SUD; relapse rates remain high, and no consistently effective medications have been established (Graddy & Rastegar, 2020; Shahrokh, 2017).

Future progress will depend on a deeper, more nuanced understanding of the disorder's heterogeneity, the exploration of novel biological targets such as neuroinflammatory and gut-brain pathways, and the development of personalized interventions that match treatment to an individual's specific neurobiological profile (Tyler & Leggio, 2024; Bartels & Schacht, 2021). By continuing to unravel the intricate biological and neurological basis of Stimulant Use Disorder, we can move beyond managing symptoms and toward developing interventions that promote lasting recovery from this debilitating condition.

---
**References**

(Note: This list is automatically generated based on the citations used in the text above. Only papers cited from the provided list are included and are formatted in APA style.)

Abdel Raheem, A. (2021). Faculty Opinions recommendation of Post-finasteride syndrome: a surmountable challenge for clinicians.. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. https://doi.org/10.3410/f.737345492.793585236
Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
Abou‐Donia, M. B. (2015). Drugs of Abuse. https://doi.org/10.1002/9781118683484.ch26
Acero Montoya, A., & Alejandra, M. (2020). Estrés laboral y sus consecuencias en la salud que afectan el rendimiento.
Adamis, D., Devaney, A., Shanahan, E., McCarthy, G., & Meagher, D. (2014). Defining ‘recovery’ for delirium research: a systematic review. Age and Ageing. https://doi.org/10.1093/ageing/afu152
Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
Adams, J., & Kirkby, R. J. (2001). Exercise Dependence and Overtraining: The Physiological and Psychological Consequences of Excessive Exercise. Sports medicine, training, and rehabilitation/Sports medicine, training and rehabilitation. https://doi.org/10.1080/10578310210395
Adinolfi, A. (2001). CONTINUING EDUCATION OFFERING. Journal of the Association of Nurses in AIDS Care. https://doi.org/10.1016/s1055-3290(06)60155-6
Adi, Y., Ashcroft, D. M., Browne, K. D., Beech, A. R., Fry-Smith, A., & Hyde, C. (2002). Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technology Assessment. https://doi.org/10.3310/hta6280
Adriani, J. (1960). The Use of Respiratory Stimulants. Postgraduate Medicine. https://doi.org/10.1080/00325481.1960.11712949
Agarwal, S., Agarwal, S., & Dayal, S. (2023). A Pilot Study to Assess the Effect of Adrenalinum 3X on Short Term and Long-term Complications of Lifestyle Disorders like Hypertension, Cancer, Diabetes, Anti-Social Behaviour, Anxiety and Depression. Acta Scientific Medical Sciences. https://doi.org/10.31080/asms.2023.07.1692
Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
Aghukwa, C. (2016). Co-morbid obsessive compulsive and hypochondriac disorders complicated by tardive dyskinesia in a Nigerian man. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1815
Ahmed, H. U. (2023). Internet addiction: issues and concerns. Bangladesh Journal of Medicine. https://doi.org/10.3329/bjm.v34i20.66121
Aizenberg, D., Zemishlany, Z., Hermesh, H., & Weizman, A. (1992). [Withdrawal reactions after clomipramine].. PubMed.
Akan, M., & Cumurcu, H. B. (2022). Cocaine use and related pathologies. Current Addiction Research. https://doi.org/10.5455/car.105-1632808119
Akerman, S., Hammel, J. L., & Brunette, M. F. (2010). Dextromethorphan Abuse and Dependence in Adolescents. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2010.537515
Akgun, Y. (2024). The potential of plasma exchange in treating

## References

1. Abdallah, S. J., Poenaru, S., Corrales‐Medina, V., & Cowan, J. (2021). COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Therapeutic Advances in Infectious Disease. https://doi.org/10.1177/20499361211009385
2. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
3. Adamis, D., Devaney, A., Shanahan, E., McCarthy, G., & Meagher, D. (2014). Defining ‘recovery’ for delirium research: a systematic review. Age and Ageing. https://doi.org/10.1093/ageing/afu152
4. Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
5. Adekeye, A. P. (2023). Psycho-social correlates of treatment-resistant depression: A Literature Review. https://doi.org/10.21428/3d48c34a.37fd141f
6. Agarwal, S., Agarwal, S., & Dayal, S. (2023). A Pilot Study to Assess the Effect of Adrenalinum 3X on Short Term and Long-term Complications of Lifestyle Disorders like Hypertension, Cancer, Diabetes, Anti-Social Behaviour, Anxiety and Depression. Acta Scientific Medical Sciences. https://doi.org/10.31080/asms.2023.07.1692
7. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
8. Ahmed, H. U. (2023). Internet addiction: issues and concerns. Bangladesh Journal of Medicine. https://doi.org/10.3329/bjm.v34i20.66121
9. Akan, M., & Cumurcu, H. B. (2022). Cocaine use and related pathologies. Current Addiction Research. https://doi.org/10.5455/car.105-1632808119
10. Aksoy, A., & Ögel, K. (2003). Kendine zarar verme davranişi.
11. Al-Thaqib, A., Kaleem, I., Baradi, R. S., Khattak, A. H., & Shahid, B. (2018). An Evaluation of the Comparative Effectiveness of tDCS Treatments for Depression in Saudi Arabia. International Journal of Neuroscience and Behavioral Science. https://doi.org/10.13189/ijnbs.2018.060102
12. Alagiakrishnan, K. (2010). Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer’s Dementia in an Elderly Woman. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.09l00905gry
13. Albertson, T. E., Chenoweth, J., Colby, D., & Sutter, M. E. (2016). The Changing Drug Culture: Medical and Recreational Marijuana.. PubMed.
14. Albuquerque, A. C. D., Silva, J. R. D., & Silva, J. (2015). The “roundabout Man” Trapped in the “roundabout City” – a Case Report of a Severe Obsessive Compulsive Disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)32056-3
15. Alderton, H. R. (1966). A Review of Schizophrenia in Childhood. Canadian Psychiatric Association Journal. https://doi.org/10.1177/070674376601100403
16. Aldweik, A. N., Hussain, K. H., & Alhaj, H. (2023). Can Functional Visual Loss Occur in an Older Adult Patient With a History of Stroke: A Case Report. BJPsych Open. https://doi.org/10.1192/bjo.2023.335
17. Alfonso‐Loeches, S., & Guerri, C. (2011). Molecular and behavioral aspects of the actions of alcohol on the adult and developing brain. Critical Reviews in Clinical Laboratory Sciences. https://doi.org/10.3109/10408363.2011.580567
18. Alghamdi, B., Zrari, M., Elahi, A. M. N., Alwagdani, M., Alghamdi, E. A. S., Moafa, H., Miran, S., Alamoudi, S., Alshahrani, K., Binnwejim, M., & jaafari, M. A. (2018). Substance abuse and its psychiatric effect on adolescence. International Journal of Community Medicine and Public Health. https://doi.org/10.18203/2394-6040.ijcmph20182450
19. Ali, A. A., Shaer, S. S. E., Gad, A. M., & Abu‐Elfotuh, K. (2017). [P1–606]: IMPACT OF PHYSICAL AND MENTAL ACTIVITIES VERSUS PROTEIN MALNUTRITION ASSOCIATED WITH SOCIAL ISOLATION DURING INDUCTION AND PROGRESSION OF ALZHEIMER's DISEASE IN RATS. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2017.06.622
20. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
21. Alim, T. N., Lawson, W., Feder, A., Iacoviello, B. M., Saxena, S., Bailey, A., Greene, A., & Neumeister, A. (2012). Resilience to meet the challenge of addiction: psychobiology and clinical considerations.. PubMed.
22. Alkan, A., Öztorun, H. S., Karcı, E., Ürün, Y., Tuncay, G., Yaşar, A., Çınar, E., Aras, S., Varlı, M., Utkan, G., Demirkazık, A., Akbulut, H., & Şenler, F. Ç. (2020). The Impact of Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients. Journal of Oncological Sciences. https://doi.org/10.37047/jos.2019-71889
23. Allen, P., Setya, A., & Lawrence, V. N. (2019). Pediatric Functional Constipation.
24. Alzahrani, H., Alharazi, M., Alzahran, G., Alroudan, D., Marwi, A., AlJamea, J., Alsubie, M., Alqahtan, A., Alzaher, M., & Alahmadi, N. (2022). Relationship of Substance Abuse and Living Situation on Burn Survivors. Journal of Healthcare Sciences. https://doi.org/10.52533/johs.2022.21208
25. Aman, M. G. (1990). Considerations in the use of psychotropic drugs in elderly mentally retarded persons. Journal of Intellectual Disability Research. https://doi.org/10.1111/j.1365-2788.1990.tb01510.x
26. Ameringen, M. V., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S., Nutt, D., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003). WCA Recommendations for the Long-Term Treatment of Social Phobia. CNS Spectrums. https://doi.org/10.1017/s1092852900006933
27. Amihăesei, I. C., & Cojocaru, E. (2014). Main neuroendocrine features, diagnosis and therapeutic possibilities in the chronic fatigue syndrome, an underdiagnosed entity.. PubMed.
28. Amoah, C., Heck, D. E., & Kim, H. D. (2022). Sensing metabolomics landscape unfold molecular connectivity between mental illness and drug abuse. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2022.18.3.0102
29. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
30. Amron, S. B., Kandasami, G., Lee, C., Guo, S. L., & Tan, H. (2025). Making sense of ICD-11 diagnostic criteria of compulsive sexual behavioural disorder. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.2024266
31. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
32. Andrade, C. (2017). Ketamine for Depression, 2: Diagnostic and Contextual Indications. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11629
33. Andréasson, S., Berglund, M., Franck, J., Fridell, M., Håkansson, I., Johansson, B., Lindgren, A., Lindgren, B., Nicklasson, L., Rydberg, U., Salaspuro, M., Thelander, S., & Öjehagen, A. (2001). Behandling av alkohol- och narkotikaproblem: En evidensbaserad kunskapssammanställning.
34. Anghel, L., Boev, M., Stănescu, C., Caramfil, S. M., Luca, L., Mușat, C. L., & Ciubară, A. (2023). Depression in the Diabetic Patient. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/14.4/526
35. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
36. Anisman, H., & Merali, Z. (1999). Understanding stress: characteristics and caveats.. PubMed.
37. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
38. Annor, E., Lokireddy, V. S., & Ramasamy, D. (2025). Prolonged Catatonia and Severe Malnutrition in Adolescents Following Bullying-Triggered Stress: A Dual Case Report. Cureus. https://doi.org/10.7759/cureus.83415
39. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
40. Appleton, R., & Gringras, P. (2013). Melatonin: helping to MEND impaired sleep. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2012-303606
41. Apter, A. (2000). Personality constellations in suicidal behavior. Éditions GREUPP eBooks. https://doi.org/10.3917/greu.isap.2000.01.0263
42. Araujo, C. F. D., Silva, R., & Leite, V. (2014). EPA-1803 - “Run, forrest, run… or don't? The case of exercise addiction”. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78921-7
43. Arendt, M., Rosenberg, R., Fjordback, L., Brandholdt, J., Foldager, L., Sher, L., & Munk-Jørgensen, P. (2007). Testing the self-medication hypothesis of depression and aggression in cannabis dependent subjects. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2007.01.601
44. Arens, C., & Schwemmle, C. (2018). [Feeding, eating, and swallowing disorders in infants and children : An overview]..
45. Aretouli, E., Malik, M., Widmann, C., Parker, A. M., Oh, E. S., & Vannorsdall, T. D. (2025). Cognitive and mental health outcomes in long covid. BMJ. https://doi.org/10.1136/bmj-2024-081349
46. Argyriadis, A., Kotrotsiou, E., Kotrotsiou, S., Katsarou, D., Patelarou, A., Patelarou, E., & Argyriadi, A. (2025). Accident-Related Stress in the Elderly: A Review of Current Trends and Implications for Mental Health. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.869
47. Ariaee, N., & Toussi, A. G. (2014). Psychological Effects of Alcohol Abuse. Asia pacific journal of medical toxicology. https://doi.org/10.22038/apjmt.2014.2898
48. Arias-Falcón, Y., Reyes-Castellano, A. J., & Pequeño-Rondón, M. M. (2020). Síndrome del niño maltratado. Revista electrónica "Dr. Zoilo E. Marinello Vidaurreta".
49. Armstrong, J. D. (1966). Responsibility and Addiction. Canadian Psychiatric Association Journal. https://doi.org/10.1177/070674376601100208
50. Arnone, J. M., & Conti, R. P. (2016). Kleine-Levin Syndrome: An Overview and Relevance to Nursing Practice. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20160219-07
51. Arnow, B. A. (2004). Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization.. PubMed.
52. Arora, A., O'Neill, A., Crome, P., & Martin, F. C. (2014). Clinical Medicine and Substance Misuse. https://doi.org/10.1002/9781118430965.ch5
53. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
54. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
55. Ashton, H., Gallagher, P., & Moore, B. P. (2006). The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106061710
56. Ashton, J. C. (2018). Is Cannabis Harmless? Focus on Brain Function. Current Drug Research Reviews. https://doi.org/10.2174/2589977511666180809165622
57. Athanasou, J. A. (2016). Substance Abuse. SensePublishers eBooks. https://doi.org/10.1007/978-94-6300-657-6_17
58. Atmazhova, O., Barzashka, E., & Stefanova, K. (2018). AMPHETAMINE AND ACUTE INTOXICATIONS. Knowledge International Journal.
59. Austin, D. S. (2015). Got Stress? You May Be Harming Your Brain. SSRN Electronic Journal.
60. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
61. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
62. Baat, C. D. (2017). Medicaments and oral healthcare 4. Pharmacotherapy in (frail and care dependent) older people. Nederlands Tijdschrift voor Tandheelkunde. https://doi.org/10.5177/ntvt.2017.05.16244
63. Babić, R., Babić, D., Martinac, M., Pavlović, M., Vasilj, I., Miljko, M., & Vasilj, M. (2018). Addictions without Drugs: Contemporary Addictions or Way of Life?. PubMed.
64. Bachmann, M., & Röhr, H.-P. (1983). A Speculative Illness Model of Over-Eating and Anorexia Nervosa. Psychological Reports. https://doi.org/10.2466/pr0.1983.53.3.831
65. Bagnell, A. (2011). Anxiety and Separation Disorders. Pediatrics in Review. https://doi.org/10.1542/pir.32.10.440
66. Baker, A., & Dawe, S. (2005). Amphetamine use and co-occurring psychological problems: Review of the literature and implications for treatment. Australian Psychologist. https://doi.org/10.1080/00050060500094654
67. Baker, D. L., & Kalivas, P. W. (2005). Sensitization and Relapse. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-852-6_15
68. Baker, D. L., Cornish, J. L., & Kalivas, P. W. (2002). Glutamate and Dopamine Interactions in the Motive Circuit. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_9
69. Baldacchino, A., & Crome, I. (2018). Epidemiological issues in mental health–substance use: a case for a life course approach to chronic disease epidemiology. CRC Press eBooks. https://doi.org/10.1201/b21790-3
70. Baldessarini, R. J., Suppes, T., & Tondo, L. (1996). LITHIUM WITHDRAWAL IN BIPOLAR DISORDER. American Journal of Therapeutics. https://doi.org/10.1097/00045391-199607000-00004
71. Baldwin, D. S. (2006). The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500600552552
72. Balhara, Y. S., Verma, R., & Mathur, S. (2011). Management of attention-deficit hyperactivity disorder. Journal of Pediatric Neurosciences. https://doi.org/10.4103/1817-1745.84400
73. Bansal, A., Saini, B., Rai, H., Dhillon, J. S., Bansal, P., & Saini, S. (2025). Dependence on ultra-high doses of gabapentinoids: A case series. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry_297_25
74. Barkin, R. L., Schwer, W. A., & Barkin, S. J. (2000). Recognition and Management of Depression in Primary Care. American Journal of Therapeutics. https://doi.org/10.1097/00045391-200007030-00008
75. Baronia, R. B. (2015). Oral Hydrocodone Induced Acute Psychosis in an Adult Male: A CaseReport.. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000535
76. Barrio, P., Seeman, M. V., & González-Rodríguez, A. (2021). Alcohol and Psychosis: A Narrative Review of the Prevalence, Clinical Manifestations, and Management of Alcohol-related Psychotic Symptoms. Current Psychiatry Research and Reviews. https://doi.org/10.2174/2666082217666210602111739
77. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
78. Barth, F. (2021). Transitions, Eating Disorders, and Changing Selves: Interlocking Psychodynamics of Identity, Self, Life Changes, and Eating Disorders. Psychoanalytic Social Work. https://doi.org/10.1080/15228878.2020.1865172
79. Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014). Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technology Assessment. https://doi.org/10.3310/hta18500
80. Bartova, L., Dold, M., Volz, H. P., Seifritz, E., Möller, H., & Kasper, S. (2025). ANTIDEPRESSANT EFFECTS OF SILEXAN IN PATIENTS WITH PRIMARY ANXIETY SYNDROMES. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.065
81. Batista, M. E. D. S., Deuner, M. C., Nascimento, G. P. V. D., Silva, L. A. D. S., & Oliveira, G. O. B. D. (2025). BENZODIAZEPINES: IMMEDIATE BENEFITS, LONG TERM RISKS. https://doi.org/10.63330/aurumpub.009-003
82. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
83. Baving, L., & Olbrich, H. M. (1996). Alcoholism and Depression. European Addiction Research. https://doi.org/10.1159/000259099
84. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
85. Beghi, M., Cornaggia, C., Frigeni, B., & Beghi, E. (2006). Learning Disorders in Epilepsy. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00681.x
86. Belt, A., Weisheit, R. A., Stalcup, S. A., & Galloway, G. P. (2013). Treating Incarcerated Juvenile Methamphetamine Abusers. Journal of Psychology Research. https://doi.org/10.17265/2159-5542/2013.08.004
87. Benbow, S. (2018). Electricity, magnetism and mood. CRC Press eBooks. https://doi.org/10.1201/9781315382913-6
88. Beninger, R. J. (2018). Life's rewards. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198824091.001.0001
89. Benowitz, N. L. (1993). Clinical Pharmacology and Toxicology of Cocaine. Pharmacology & Toxicology. https://doi.org/10.1111/j.1600-0773.1993.tb01331.x
90. Bergman, B., & Brismar, B. (1998). The Significance of Alcohol for Violence and Accidents. Alcoholism Clinical and Experimental Research. https://doi.org/10.1097/00000374-199807001-00004
91. Bernaards, C. M. (2006). Role of physical activity in preventing mental health problems.
92. Bersselaar, L. R. V. D., Hoeven, J. G. V. D., & Jong, B. D. (2020). Feeling Death, Being Alive: 4-Methylethcathinone/Pentedrone Addiction and 3-Methoxyphencyclidine Intoxication. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0000000000000214
93. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
94. Beutler, B. D., Shinozuka, K., Tabaac, B. J., Arenas, A., Cherian, K., Evans, V. D., Fasano, C., & Muir, O. S. (2023). Psychedelic Therapy: A Primer for Primary Care Clinicians – Part II. Lysergic acid diethylamide (LSD). https://doi.org/10.31234/osf.io/km7nu
95. Beutler, B. D., Shinozuka, K., Tabaac, B. J., Arenas, A., Cherian, K., Evans, V. D., Fasano, C., & Muir, O. S. (2024). Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD). American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001726
96. Bixquert, M. (2013). Treatment of irritable bowel syndrome with probiotics: growing evidence.. PubMed.
97. Bjork, J. M., & Thomson, N. D. (2020). Stress and Substance Misuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190920197.003.0006
98. Black, D. W. (2015). Compulsive Shopping as a Behavioral Addiction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199391547.003.0006
99. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
100. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
101. Blumenthal, J. A., & Lett, H. S. (2005). Depression and Cardiac Risk. Journal of Cardiopulmonary Rehabilitation. https://doi.org/10.1097/00008483-200503000-00005
102. Bobo, W. V., Miller, S. C., & Martin, B. D. (2005). The Abuse Liability of Dextromethorphan Among Adolescents: A Review. Journal of Child & Adolescent Substance Abuse. https://doi.org/10.1300/j029v14n04_04
103. Bokin, K. (2021). Psychotherapy Utilization among Old People with Post-Traumatic Stress Disorder. Journal of Yoga & Physical Therapy. https://doi.org/10.35248/2157-7595.21.s6.004
104. Bolton, E., Holohan, D. R., King, L. A., & King, D. W. (2004). Acute and Post-Traumatic Stress Disorder. Routledge eBooks. https://doi.org/10.4324/9780203336960-13
105. Bonet, N. A. D., Sánz, P., Canals, M. L., & Martí-Amengual, G. (2020). Fatal accident involving a welder employed by a shipping container company, associated with the use of tramadol and antidepressant agents. International Maritime Health. https://doi.org/10.5603/imh.2020.0020
106. Bonsack, C. (2014). Le désavantage social des troubles mentaux : épidémie, invalidation ou stigmatisation. Schweizer Archiv für Neurologie und Psychiatrie. https://doi.org/10.4414/sanp.2014.00293
107. Bordini, L., Riboldi, L., & Ferrario, M. (2013). [Psychotropic substances and driving].. PubMed.
108. Borowski, M. (2013). Addiction as a Disease. European Researcher. https://doi.org/10.13187/er.2013.55.1945
109. Bossini, L., Coluccia, A., Casolaro, I., Benbow, J., Amodeo, G., Giorgi, R. D., & Fagiolini, A. (2015). Off-Label Trazodone Prescription: Evidence, Benefits and Risks. Current Pharmaceutical Design. https://doi.org/10.2174/1381612821666150619092236
110. Boylan, K., & Eppel, A. (2008). The severe mood dysregulation phenotype: case description of a female adolescent.. PubMed.
111. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
112. Brady, K. T., & Lydiard, B. (1992). Bipolar Affective Disorder and Substance Abuse. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199202001-00004
113. Brahm, N. C., & Fast, G. A. (2009). Increased Sexual Aggression Following Ziprasidone Discontinuation in an Intellectually Disabled Adult Man. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.08l00722
114. Brandt, J., Butters, N., Ryan, C. M., & Bayog, R. (1983). Cognitive Loss and Recovery in Long-term Alcohol Abusers. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1983.01790040089012
115. Bricou, O., Taïeb, O., Baubet, T., Gal, B., Guillevin, L., & Moro, M. R. (2006). Stress and Coping Strategies in Systemic Lupus Erythematosus: A Review. NeuroImmunoModulation. https://doi.org/10.1159/000104856
116. Brito, A. D. S. (2015). Alcoolismo associado a transtornos mentais..
117. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1177/10598405050210060301
118. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1622/1059-8405(2005)021[0318:tuoais]2.0.co;2
119. Brust, J. C. (2002). Neurologic Complications of Substance Abuse. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/00126334-200210012-00002
120. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
121. Brüne, M., & Kahlert, I. (2001). Über einen Fall von primärer Zopiclonabhängigkeit. DMW - Deutsche Medizinische Wochenschrift. https://doi.org/10.1055/s-2001-14488
122. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
123. BS, R. A., & Veronica, A. S. (2016). Synthetic Cannabinoids and Dysphonia: A Case Report. Journal of General Practice. https://doi.org/10.4172/2329-9126.1000220
124. Buckley, P. (1998). Substance abuse in schizophrenia: a review.. PubMed.
125. Buckley, P. (2006). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness.. PubMed.
126. Buckley, P., & Brown, E. S. (2006). Prevalence and Consequences of Dual Diagnosis. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.0706e01
127. Burgić-Radmanović, M. (2011). Affective disorders in childhood and adolescence. Acta Medica Academica. https://doi.org/10.5644/ama.v40i1.103
128. Burk, A., Merchant, A., Rahman, H., Patel, A., Deshmukh, I., Merchant, R., Yam, A. A., Yu, A., Cai, C., Hassam, A., Le, D., & Lambroussis, C. G. (2025). Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult. Cureus. https://doi.org/10.7759/cureus.86587
129. Burke, C., Anglin, M. D., Perrochet, B., Stamper, E. S., & Dawud‐Noursi, S. (2000). History of the Methamphetamine Problem. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2000.10400221
130. Burt, V. K. (2004). Plotting the course to remission: the search for better outcomes in the treatment of depression.. PubMed.
131. Buss, T., & Modlińska, A. (2004). [Cancer-related fatigue. II. Causes and management of the problem]..
132. Buss, T., Modlińska, A., Chełmińska, M., & Niedoszytko, M. (2004). Cancer related fatigue. I. Prevalence and attempt to define the problem.
133. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
134. Bürk, K., Strelczyk, A., & Oertel, W. H. (2012). Intermittent Tunnel Vision in a Patient With Multiple Drug Abuse History. Movement Disorders. https://doi.org/10.1891/9781617050589.0090
135. Cabanis, M., Outadi, A., & Choi, F. (2021). Early childhood trauma, substance use and complex concurrent disorders among adolescents. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0000000000000718
136. Cabero, M. D. L. H., López, S. B., Borrego, N., Carrascal, I. O., Flores, L., & Rico, R. J. (2016). Obsessive symptoms in schizophrenia: A case report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.2122
137. Cabrejo-Mendoza, H. J., & Albornoz-Muñoz, D. P. (2023). Trastorno de Acumulación: A propósito de un caso. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v86i1.4469
138. Cadet, J. L. (2014). Epigenetics of Stress, Addiction, and Resilience: Therapeutic Implications. Molecular Neurobiology. https://doi.org/10.1007/s12035-014-9040-y
139. Camacho, M., Moura, A. R., & Oliveira‐Maia, A. J. (2018). Compulsive Sexual Behaviors Treated With Naltrexone Monotherapy. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.17l02109
140. Campos, R. C. (2017). Striatum, Dopamine and Automatism in Cocaine Addiction and Relapse : Pharmacological and Behavioral Investigation.
141. Carbone, M. G., Pagni, G., Tagliarini, C., Maremmani, I., & Maremmani, A. G. I. (2025). Caffeine in Aging Brains: Cognitive Enhancement, Neurodegeneration, and Emerging Concerns About Addiction. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph22081171
142. Carnovale, C., Pellegrino, P., Perrone, V., Antoniazzi, S., Pozzi, M., Nisic, A., Clementi, E., & Radice, S. (2013). Neurological and psychiatric adverse events with prucalopride: case report and possible mechanisms. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1111/jcpt.12087
143. Cascino, G. D. (2004). Intractable partial epilepsy of left frontal lobe origin related to focal cortical dysplasia. https://doi.org/10.1093/oso/9780195177442.003.0004
144. Casey, P. (2018). Making the diagnosis in clinical practice (DRAFT). Oxford University Press eBooks. https://doi.org/10.1093/med/9780198786214.003.0006
145. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
146. Casper, R. C. (2018). Not the Function of Eating, but Spontaneous Activity and Energy Expenditure, Reflected in “Restlessness” and a “Drive for Activity” Appear to Be Dysregulated in Anorexia Nervosa: Treatment Implications. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2018.02303
147. Castellanos, G., Escobar, A. P., & González, B. G. (2006). Estrés y conducta adictiva. DELETED.
148. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
149. Chandler, J. A., Mogyoros, A., Rubio, T. M., & Racine, É. (2013). Another Look at the Legal and Ethical Consequences of Pharmacological Memory Dampening: The Case of Sexual Assault. The Journal of Law Medicine & Ethics. https://doi.org/10.1111/jlme.12096
150. Chandran, S., Kishor, M., Maheshwari, S., Mathur, S., & Rao, T. S. (2018). Nonresponsive responder! –Somatic symptoms presenting as refractory depression with response to electroconvulsive therapy. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_2_18
151. Chang, A. N., Kiyokawa, M., & Grysman, N. (2025). Cocaine Induced Postictal Psychosis: a Rare Cause of Antipsychotic Resistant Psychosis. Hawai‘i Journal of Health &amp Social Welfare. https://doi.org/10.62547/nmiq4624
152. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
153. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
154. Charmaz, K. (2007). Chronic Illness and Disability. The Blackwell Encyclopedia of Sociology. https://doi.org/10.1002/9781405165518.wbeosc035
155. Chavan, R., Gosavi, M., Baviskar, M., & Goyal, N. P. (2023). Depression Detection using AI, ML and NLP. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-8886
156. Chaves, T. V. (2019). Through ketamine fields: pain and afterglow. https://doi.org/10.33612/diss.107955714
157. Chen, C., Liang, T., Ko, C., & Hsieh, H. (2022). The effectiveness of <scp>real‐time</scp> identification of medication ingestion in schizophrenic patients in Taiwan. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12637
158. Chen, H., Albertson, T. E., & Olson, K. R. (2015). Treatment of drug‐induced seizures. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12720
159. Cheng, C., & Tsai, S. (2014). Persistent hiccups associated with switching from paliperidone to amisulpride. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12239
160. Chevallier, B., & Refinetti, P. (2020). [Dangerous practices and games at school].. PubMed.
161. Chicoș, O., Perri, D., Capriș, L., Iliescu, A. I. B., & Kantor, C. (2019). Social-Cultural Influences and Personality Disorders Favoring Drug Consumption. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s1/3
162. Cho, Y.-R., Kim, H.-W., Lee, J.-I., Yun, J.-S., Lee, J. S., & Woo, Y.-S. (2008). A Case of Fluoxetine Induced Mania in Poststroke Depression Patient -A case report-. Annals of Rehabilitation Medicine.
163. Chuen, L. H. (2022). Traditional Chinese Medicine Offers Help to Marijuana Users Determined to Withdraw Report of Two Typical Cases. Journal of Drugs Addiction & Therapeutics. https://doi.org/10.47363/jdat/2022(3)121
164. Chummun, H., Tilley, V., & Ibe, J. (2010). 3,4-methylenedioxyamfetamine (ecstasy) use reduces cognition.. British Journal of Nursing.
165. Chumpitazi, C. E. (2018). Minor Adverse Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190659110.003.0022
166. Cienfuegos, J. J., Arriaga, M. Á. A., García, J. J., & Fernández, A. C. S. (2021). Propuesta de establecimiento de hábitos y rutinas que contemplen ejercicio y manejo del estrés para evitar el desgaste laboral durante el home office. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v5i3.583
167. Cl, T., Yee, A., Sm, M., Oh, K., & Cg, N. (2010). Antidepressant induced Mania and Steroid Psychosis in a Patient with Bell’s Palsy. The Malaysian journal of psychiatry.
168. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
169. Clayton, A. H. (2007). Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.8.4.457
170. Coelho, C. M. M., Santos, G. X. C., Magano, S., Mota, D., Ferreira, S., Araújo, A. I., Cabaços, C., & Macedo, A. (2019). Treatment of Depersonalization-derealization Disorder With Transcranial Magnetic Stimulation. https://doi.org/10.26226/morressier.5d1a037457558b317a1404e8
171. Colado, M. I., O’Shea, E., & Green, A. R. (2007). MDMA and Other “Club Drugs”. https://doi.org/10.1002/9780470101001.hcn039
172. Collo, G., & Pich, E. M. (2018). Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.230288
173. Coman, H., & Herţa, D.-C. (2022). Psychiatry of disasters. Psihiatru ro. https://doi.org/10.26416/psih.71.4.2022.7329
174. Coman, H., Cozman, D., Buciuta, A., & Nemeş, B. (2019). Treatment management of psychoactive substance use disorders. Psihiatru ro. https://doi.org/10.26416/psih.59.4.2019.2604
175. Compton, D. M., Dewey, W. L., & Martin, B. R. (1990). Canabis Dependence and Tolerance Production. Advances in Alcohol & Substance Abuse. https://doi.org/10.1300/j251v09n01_08
176. Compton, W. M., Grant, B. F., Colliver, J. D., Glantz, M. D., & Stinson, F. S. (2017). Prevalence of Marijuana Use Disorders in the United States.
177. Conaglen, H. M., & Conaglen, J. V. (2013). Drug-induced sexual dysfunction in men and women. Australian Prescriber. https://doi.org/10.18773/austprescr.2013.021
178. Condie, L. O. (2021). Parents with Brain Impairment. CRC Press eBooks. https://doi.org/10.4324/9781003213307-18
179. Consroe, P., & Snider, S. R. (2019). Therapeutic Potential of Cannabinoids in Neurological Disorders * , †. Chapman and Hall/CRC eBooks. https://doi.org/10.1201/9780429260667-2
180. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
181. Copeland, J., Clement, N., & Swift, W. (2014). Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry. https://doi.org/10.2217/npy.13.90
182. Corbett, A., Burns, A., & Ballard, C. (2014). Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. https://doi.org/10.1136/bmj.g6420
183. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
184. Correia‐Melo, F. S., Silva, S. S., Araújo-de-Freitas, L., & Quarantini, L. C. (2017). S-(+)-ketamine-induced dissociative symptoms as a traumatic experience in patients with treatment-resistant depression. Brazilian Journal of Psychiatry. https://doi.org/10.1590/1516-4446-2016-2070
185. Correll, C. U., Kratochvil, C. J., & March, J. S. (2011). Developments in Pediatric Psychopharmacology. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11r07064
186. Covington, H. E., & Miczek, K. A. (2010). Binge Drug Taking. Neuromethods. https://doi.org/10.1007/978-1-60761-934-5_15
187. Creado, S., Plante, D., & Casey, K. R. (2017). 1220 Veteran with Sleep Eating, Post-traumatic Stress Disorder and Severe Obstructive Sleep Apnea. SLEEP. https://doi.org/10.1093/sleepj/zsx052.010
188. Cristofor, A.-C., Popa, T., Crețeanu, A., Rusu, G., & Mititelu-Tarțău, L. (2016). Farmacoterapia depresiei la pacientul vârstnic. Farmacist ro.
189. Cruickshank, C., & Dyer, K. R. (2009). A review of the clinical pharmacology of methamphetamine. Addiction. https://doi.org/10.1111/j.1360-0443.2009.02564.x
190. Cuevas, M. J. S. (2005). EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD (314.01) Y SU INCIDENCIA EN EL MEDIO ESCOLAR, FAMILIAR Y SOCIAL EN EL CAMPO DE GIBRALTAR. Almoraima:  revista de estudios campogibraltareños.
191. Cummings, P. M., Trelka, D. P., & Springer, K. M. (2013). Poisoning. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511920905.007
192. Dadić-Hero, E., Ružić, K., Medved, P., Vorkapić, S. T., & Graovac, M. (2010). Antipsychotic side-effect - potential risk of patients rejecting their treatments.. PubMed.
193. Daley, D. C., & Douaihy, A. (2006). Medications in Dual Recovery. https://doi.org/10.1093/oso/9780195311297.003.0006
194. Daley, D. C., & Douaihy, A. (2006). The Recovery Process for Addiction and Mood Disorders. https://doi.org/10.1093/oso/9780195311297.003.0004
195. Daley, D. C., & Douaihy, A. (2019). Effects of Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0004
196. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
197. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
198. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
199. Das, C., & Joseph, S. (2005). Falls in elderly.. PubMed.
200. Davies, J. B., Saunders, W., & Helfgott, S. (2018). What is addiction?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0001
201. Deas, D., & Brown, E. S. (2006). Adolescent Substance Abuse and Psychiatric Comorbidities. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.0706e02
202. Deaver, L. N. (2021). Chronically irritable mood with frequent temper outbursts. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0009
203. Delanerolle, G., Shetty, S., Raymont, V., Hapangama, D. K., Haque, N., Shi, J. Q., Ayis, S., Shetty, A., & Phiri, P. (2021). None. LOJ Medical Sciences. https://doi.org/10.32474/lojms.5.5
204. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
205. Demaret, I., Lemaître, A., & Ansseau, M. (2013). [Heroin].. PubMed.
206. Demirkıran, M., Jankovic, J., & Dean, J. M. (1996). Ecstasy Intoxication: An Overlap Between Serotonin Syndrome and Neuroleptic Malignant Syndrome. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-199619020-00004
207. Desousa, A., Sathe, H., Phirke, M., Shah, N., & Sonavane, S. (2017). Electroconvulsive in a 75-year-old patient with severe agitated behavior and dementia. Journal of Geriatric Mental Health. https://doi.org/10.4103/jgmh.jgmh_49_16
208. Devlin, R. J., & Henry, J. A. (2008). Clinical review: Major consequences of illicit drug consumption. Critical Care. https://doi.org/10.1186/cc6166
209. Diarra, E., Jedynak, C. P., & Verny, M. (2008). [Tremor in the elderly].. PubMed. https://doi.org/10.1684/pnv.2008.0139
210. Diener, H., Holle, D., Dresler, T., & Gaul, C. (2018). Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2018.0365
211. DiFazio, M., Silverberg, N. D., Kirkwood, M. W., Bernier, R., & Iverson, G. L. (2015). Prolonged Activity Restriction After Concussion. Clinical Pediatrics. https://doi.org/10.1177/0009922815589914
212. DiFranza, J. R., Wellman, R. J., Mermelstein, R. J., Pbert, L., Klein, J. D., Sargent, J. D., Ahluwalia, J. S., Lando, H. A., Ossip, D. J., Wilson, K. M., Balk, S. J., Hipple, B., Tanski, S. E., Prokhorov, A. V., Best, D., & Winickoff, J. P. (2011). The Natural History and Diagnosis of Nicotine Addiction. Current Pediatric Reviews. https://doi.org/10.2174/157339611795735648
213. Dilsaver, S. C., Halle, M. H., & Medico, V. J. D. (1991). Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1991.tb05531.x
214. DiMartini, A. (2007). Natural history of alcohol use disorders in liver transplant patients. Liver Transplantation. https://doi.org/10.1002/lt.21342
215. Diwan, P. V., & Dikshith, T. S. S. (2003). Nonmedical Use of Drugs. https://doi.org/10.1002/0471426075.ch14
216. Dobrescu, I., Rad, F., Anghel, G. C., Stancu, M., & Buică, A. (2017). P288 Somatic complaints in anxiety disorders. https://doi.org/10.1136/archdischild-2017-313273.376
217. Dolenc, T. J. (2015). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214883.003.0044
218. Dorard, G., & Benarbia, A. (2017). Chemsex : definition and healthcare access matter. European Health Psychologist.
219. DRISCOLL, P. L. (2009). MAINTENANCE MEDICATION FOR CHRONIC SCHIZOPHRENICS: RISK/BENEFIT ASSESSMENT. Perspectives In Psychiatric Care. https://doi.org/10.1111/j.1744-6163.1985.tb00264.x
220. Drogin, E. Y., Dattilio, F. M., Sadoff, R. L., & Gutheil, T. G. (2011). Appendix A: Scientific Glossary. https://doi.org/10.1002/9781118093399.app1
221. Dunnigan, M., Czapla, K., Henderson, J. B., & Pelosi, A. J. (1999). The Fluid Retention Syndrome: Recognition, Risk Factors and Management. The Journal of the British Menopause Society. https://doi.org/10.1177/136218079900500206
222. Díez‐Tejedor, E., Tejada, J. H., & Frank, A. (1989). [Neurologic complications caused by use of cocaine, amphetamines and sympathomimetics].. PubMed.
223. d’Andrea, G., Marco, O. D., Semeraro, F. M., Carullo, R., Sensi, S. L., Pettorruso, M., & Martinotti, G. (2023). Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100188
224. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
225. Ebmeier, K. P. (2010). Normal cognitive decline or dementia?. Practitioner.
226. Edge, R., & Argáez, C. (2021). Droperidol for Agitation in Acute Care [Internet].
227. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
228. Efron, D., Wu, C., Prakash, C., & Donley, M. (2025). “Chemical Restraint” for Children and Adolescents in Victoria. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16800
229. Eiden, C., Cathala, P., Fabresse, N., Galea, Y., Mathieu-Daudé, J.-C., Baccino, É., & Peyrière, H. (2013). A Case of Drug-Facilitated Sexual Assault Involving 3,4-methylene-dioxy-methylamphetamine. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2013.763573
230. Ekhart, C., Hunsel, F. V., Sellick, V., & Vries, T. W. D. (2022). Neuropsychiatric reactions with the use of montelukast. BMJ. https://doi.org/10.1136/bmj-2021-067554
231. Ekinci, N., Güneş, S., Ekıncı, O., Kalınlı, M., Okuyaz, Ç., & Direk, M. Ç. (2019). Levetiracetam-Related Mania-Like Symptoms: An Adolescent Case. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000335
232. El-Hamady, M. M., El-Sayed, H., Bakry, S. E., & Youniss, M. (2020). Prevalence of Anxiety Disorders in Substance Related Disorders. Benha Journal of Applied Sciences. https://doi.org/10.21608/bjas.2020.137193
233. Ensalada, L. H., Brigham, C. R., & Kertay, L. (2018). Somatization. AMA guides newsletter. https://doi.org/10.1001/amaguidesnewsletters.2018.julaug03
234. Ertem, D. H., Maner, F., & Köksal, A. (2013). Text messaging as a new compulsive behavior in a patient with <scp>P</scp>arkinson's disease. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12015
235. Escayola, E. N., Caballero, J. M. M.-Q., & Valencia, B. C. (2014). Valoración médico forense de muerte en custodia por delirium agitado. A propósito de un caso.
236. Esmaeilpour, F., Iderapalli, M., & Ugoh, E. (2025). Effective Management of Ketamine-Induced Bladder Syndrome With Baclofen During Ketamine Detoxification: A Case Report. BJPsych Open. https://doi.org/10.1192/bjo.2025.10724
237. Espinosa‐Jovel, C., & Sobrino, F. (2017). Caffeine and headache: specific remarks. Neurología (English Edition). https://doi.org/10.1016/j.nrleng.2014.12.022
238. Espiridion, E. D., & Risos, K. N. (2018). A Major Depressive Disorder in a Patient with Pseudobulbar Affect. Cureus. https://doi.org/10.7759/cureus.3746
239. Estroff, T. W., & Gold, M. S. (2022). Medical and Psychiatric Complications of Cocaine Abuse With Possible Points of Pharmacological Treatment. Routledge eBooks. https://doi.org/10.4324/9781003282822-6
240. Ettensohn, M. F., Markey, S. M., & Levine, S. P. (2018). Considering Ketamine for Treatment of Comorbid Pain, Depression, and Substance Use Disorders. Psychiatric Annals. https://doi.org/10.3928/00485713-20180312-02
241. Evans, R. W. (2008). Treating migraine in the emergency department. BMJ. https://doi.org/10.1136/bmj.39560.696748.80
242. Faeder, M., Hale, E., Hedayati, D., Israel, A., Moschenross, D., Peterson, M., Peterson, R., Piechowicz, M., Punzi, J., & Gopalan, P. (2023). Preventing and treating delirium in clinical settings for older adults. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231198462
243. Falk, A., Joseph, R., Smith, S., & Wilk, A. (2023). Mood and Anxiety Disorders: Major Depressive Disorder.. PubMed.
244. Falk, J. L. (2019). Excessive Behavior and Drug-Taking: Environmental Generation and Self-Control. Routledge eBooks. https://doi.org/10.4324/9780429307898-4
245. Farah, R., & Farah, R. (2008). Ecstasy (3,4-Methylenedioxymethamphetamine)-Induced Inappropriate Antidiuretic Hormone Secretion. Pediatric Emergency Care. https://doi.org/10.1097/pec.0b013e3181850c91
246. Farnsworth, M. G. (1990). Benzodiazepine abuse and dependence: misconceptions and facts.. PubMed.
247. Farrell, B., Hughes, L., Neutel, I., & Babcock, K. (2003). Facilitating the Process of Medication Re-evaluation and Withdrawal in the Long-Term Institutionalized Population: The Example of Cisapride. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v56i1.407
248. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
249. Ferigolo, M., Machado, A. G. D. S., Oliveira, N., & Barros, H. M. T. (2003). Ecstasy intoxication: the toxicological basis for treatment. Revista do Hospital das Clínicas. https://doi.org/10.1590/s0041-87812003000600008
250. Fessas, P., & Duret, A. (2018). Question 1: Is there a role for the ketogenic diet in refractory status epilepticus?. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2018-315755
251. Fineberg, N., Reghunandanan, S., Brown, A., & Pampaloni, I. (2012). Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867412461958
252. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
253. Finlay‐Jones, A., Parkinson, A., Sirois, F. M., Perry, Y., Boyes, M., & Rees, C. S. (2023). Web-Based Self-Compassion Training to Improve the Well-Being of Youth With Chronic Medical Conditions: Randomized Controlled Trial. Journal of Medical Internet Research. https://doi.org/10.2196/44016
254. Fipps, D. C., & Sinha, S. (2023). Substance Use Disorders and Sleep. Psychiatric Annals. https://doi.org/10.3928/00485713-20231019-01
255. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
256. Fitzgerald, C., & Patten, S. B. (2008). Is Multiple Sclerosis Patient Depressed, Stressed, or Both? How to Sort through Overlapping Symptoms and Provide Appropriate Treatment. Current psychiatry.
257. Flores, C. (2010). FACTORES QUE INFLUYEN EN LA ADICCIÓN ADOLESCENTE. Contribuciones a las Ciencias Sociales.
258. Forouzan, S., McGrew, K., & Kosten, T. A. (2021). Drugs and bugs: Negative affect, psychostimulant use and withdrawal, and the microbiome. American Journal on Addictions. https://doi.org/10.1111/ajad.13210
259. Fouwels, A., & Timmer, T. J. (2007). [Choking caused by antipsychotics].. PubMed.
260. Fox, C., Jimoh, F. O., & Cross, J. (2018). Intervention to prevent, delay or reduce frailty in community-living older adults..
261. Franjić, S. (2023). Child Abuse and Neglect is a Serious Problem in Every Society. Deleted Journal. https://doi.org/10.33140/jre.01.01.03
262. Franken, I. H. A., & Wiers, R. W. (2013). [Motivational processes in addiction: the role of craving, salience and attention].. PubMed.
263. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
264. Fries, A., Christ, M., Nickl, H., Spreer, M., Pilhatsch, M., & Petzold, J. (2025). The Diagnosis and Treatment of Stimulant-Related Emergencies.. PubMed. https://doi.org/10.3238/arztebl.m2025.0158
265. Fulga, A., Neagu, A., Ciubară, A., Mușat, C. L., Neagu, M., & Fulga, I. (2019). Pro-active Drug Facilitated Sexual Assault Using Sedative - hypnotic Medication. Revista de Chimie. https://doi.org/10.37358/rc.70.19.11.7706
266. Ga, H. (1990). [Hormone substitution in the female climacteric--goals, means, effects].. PubMed.
267. Gable, M., & Depry, D. (2015). Psychosis Requiring Hospitalization in an Adult ADHD Patient on a Therapeutic Stimulant: A Case Report and Review of Treatment Alternatives. International Journal of Clinical Case Studies. https://doi.org/10.15344/2455-2356/2015/103
268. Galanter, M. (2014). Network Therapy for Substance Use Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg60
269. Galasko, D. (2019). Pharmacological Approaches To Behavioral Symptoms In Alzheimer’s Disease. CRC Press eBooks. https://doi.org/10.1201/9780429260353-28
270. Gameiro, G. R., Minguini, I. P., & Alves, T. C. T. F. (2014). O papel do estresse e de acontecimentos cotidianos para o desenvolvimento da depressão na terceira idade. Revista de Medicina. https://doi.org/10.11606/issn.1679-9836.v93i1p31-40
271. Ganasan, S. (2019). Managing depression in the primary care setting. Journal of Prescribing Practice. https://doi.org/10.12968/jprp.2019.1.8.388
272. Ganz, D., & Lindenfeld, L. (2009). Suicidal behavior in adolescents with comorbid depression and alcohol abuse.. PubMed.
273. García, E., García, L. C., Villarroel, C. M., Revuelta, M. S., Cutanda, J. D., & Matsuura, J. (2021). Obsessive symptoms as first alert of psychosis: Two cases report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1625
274. Garg, T., & Rawat, V. S. (2023). Trihexyphenidyl Use Disorder and Withdrawal Syndrome. Journal of Psychiatry Spectrum. https://doi.org/10.4103/jopsys.jopsys_12_23
275. Gautam, S., Gautam, M., Yadav, K. S., Chaudhary, J., & Jain, A. (2023). Clinical Practice Guidelines for Assessment and Management of Aggressive and Assaultive Behaviour. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_518_22
276. Gałuszko‐Węgielnik, M., Chmielewska, Z., Jakuszkowiak‐Wojten, K., Wiglusz, M. S., & Cubała, W. J. (2023). Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression. Brain Sciences. https://doi.org/10.3390/brainsci13010142
277. Geissler, K. (1990). [Does the pill have a psychotropic effect?].. PubMed.
278. Gentile, J. P. (2018). Aggression in Intellectual Disability. International Journal of Autism & Related Disabilities. https://doi.org/10.29011/2642-3227.000010
279. George, O., Ahmed, S. H., & Gilpin, N. W. (2022). Are we compulsively chasing rainbows?. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01419-w
280. Gerada, C. (2018). Serious mental illness and dual diagnosis. CRC Press eBooks. https://doi.org/10.4324/9781315383231-9
281. Gervis, M. (2013). Emotional Abuse in Sport: A Case Study of Trichotillomania in a Prepubescent Female Gymnast. Journal of Clinical Case Reports. https://doi.org/10.4172/2165-7920.1000264
282. Ghaisani, N. (2018). Potensi Ketamin Dosis Rendah untuk Penderita Depresi Berat. JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia.
283. Ghodse, H., & Galea, S. (2023). Misuse of drugs and alcohol. CRC Press eBooks. https://doi.org/10.1201/9781846197062-3
284. Giannopoulos, I., Jupe, T., & Provi, K. (2024). Sleep architecture disturbance due to the use of benzodiazepines. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1614
285. Giannopoulos, I., Jupe, T., & Roumpou, A. (2024). Sexual dysfunction, depression, and the impact of antidepressants. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1120
286. Giasuddin, N. A., & Hossain, M. J. (2020). Understanding Obsessive Compulsive Disorder and Management Options. Faridpur Medical College Journal. https://doi.org/10.3329/fmcj.v15i1.49009
287. Giménez, V. M. M., Mazzei, L., Sanz, R., & Manucha, W. (2022). Cannabinoids as Potential Molecules for Addiction Disorders. Current Protein and Peptide Science. https://doi.org/10.2174/1389203723666220510121031
288. Girolamo, G. D., Dagani, J., Purcell, R., Cocchi, A., & McGorry, P. D. (2011). Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796011000746
289. Givler, D., Givler, A., Luther, P. M., Wenger, D. M., Ahmadzadeh, S., Shekoohi, S., Edinoff, A. N., Dorius, B., Baptiste, C. J., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2023). Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurology International. https://doi.org/10.3390/neurolint15010031
290. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking. JAMA. https://doi.org/10.1001/jama.264.12.1583
291. Glass, R. M. (1990). Blue mood, blackened lungs. Depression and smoking.. PubMed.
292. Goeders, N. E. (2004). Stress, Motivation, and Drug Addiction. Current Directions in Psychological Science. https://doi.org/10.1111/j.0963-7214.2004.01301009.x
293. Gold, M. S. (2005). Dual Diagnosis. Journal of Dual Diagnosis. https://doi.org/10.1300/j374v01n01_02
294. Goldberg, J. F., Singer, T. M., & Garno, J. L. (2001). Suicidality and substance abuse in affective disorders.. PubMed.
295. Goldfeder, S., Scott, R., & Briggs, J. P. (2023). Forensic Assessments of Alcohol, Cannabis and Methamphetamine Intoxication in Cases of Violent Offending.. PubMed.
296. Gomathy, S. B., Saini, A., Gupta, A., Vishnu, V. Y., Singh, M. B., Bhatia, R., Srivastava, M. P., Radhakrishnan, D. M., Srivastava, A. K., & Rajan, R. (2024). A rare yet treatable case of paroxysmal kinesigenic dyskinesia. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_28_23
297. Gombru, A., Brignell, G., & Donnelly, H. (2016). Sentencing for domestic violence.
298. Gooblar, J., & Beaudreau, S. A. (2018). Anxiety Disorders in Late Life. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.415
299. Gordon, M., & Melvin, G. (2014). Prescribing for depressed adolescents: Office decision-making in the face of limited research evidence. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.12517
300. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
301. Graddy, R., & Rastegar, D. A. (2025). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0008
302. Granger, C. E., & Shelly, M. P. (1996). Stressing out, or outing stress?. European Journal of Anaesthesiology. https://doi.org/10.1097/00003643-199611000-00001
303. Gregorowski, C., Seedat, S., & Jordaan, G. P. (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-289
304. Greist, J. H. (1990). Treatment of obsessive compulsive disorder: psychotherapies, drugs, and other somatic treatment.. PubMed.
305. Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Montgomery, S., Nutt, D., Okasha, A., Swinson, R. P., & Zohar, J. (2003). WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults. CNS Spectrums. https://doi.org/10.1017/s1092852900006908
306. Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Okasha, A., Zohar, J., Allgulander, C., Cassano, G. B., Pollack, M. S., & Ameringen, M. V. (2003). Recommendations for the Long-Term Treatment of Anxiety Disorders.
307. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Anxiety disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.007
308. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Substance abuse disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.016
309. Griffiths, M. D., Hodgson, R. J., & Budd, R. (2001). Compulsive Behaviours. Contemporary psychiatry. https://doi.org/10.1007/978-3-642-59519-6_131
310. Gupta, R., Singh, A. P., Mittal, A., & Chaturvedi, S. K. (2024). "FROM BOOST TO BREAKDOWN "PERFORMANCE ENHANCEMENT AND THE DARK SIDE OF MEPHENTERMINE ADDICTION” A CASE SERIES. Global Journal For Research Analysis. https://doi.org/10.36106/gjra/0506138
311. Guszkowska, M. (2013). [Exercise dependence--symptoms and mechanisms].. PubMed.
312. Gómez, M. V. (2005). Cefalea crónica diaria: II. Tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.4003.2004387
313. Gündoğmuş, İ., Karagöz, A., & Algül, A. (2018). First-episode psychosis induced by pregabalin withdrawal: a case report. Psychiatry and Clinical Psychopharmacology. https://doi.org/10.1080/24750573.2018.1452523
314. Güngörmüş, Z., & Özgüç, S. (2025). Psychosocial problems observed in older adults after disaster. Psychogeriatrics. https://doi.org/10.1111/psyg.70001
315. Hall, P. A., & Burhan, A. M. (2022). Commentary on Song <i>et al</i>: Brain stimulation for addictions‐ optimizing impact via strategic interleaving with pharmacotherapy, cognitive behavioral therapy, and restructuring the micro‐environment. Addiction. https://doi.org/10.1111/add.15797
316. Hall, S. W. (2011). Idiopathic Environmental Intolerances. SpringerReference. https://doi.org/10.1007/springerreference_44303
317. Hall, S., & Ibrahim, S. (2023). 0998 Duloxetine as a Possible Effective Treatment of Klein-Levin Syndrome Case Report. SLEEP. https://doi.org/10.1093/sleep/zsad077.0998
318. Hall, W., Talbert, R. L., & Ereshefsky, L. (1990). Cocaine Abuse and Its Treatment. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/j.1875-9114.1990.tb02550.x
319. Hartston, H. (2012). The Case for Compulsive Shopping as an Addiction. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2012.660110
320. Hawes, D. J., & Scalise, P. (2005). Childhood depression: early risk and resilience and introducing solids to infants. https://doi.org/10.4225/50/5552facc15227
321. Hayes, A., & Lingford‐Hughes, A. (2023). Drug Use, Addiction, Tolerance, Withdrawal and Relapse. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.058
322. Hayman, M. (1966). The medical practitioner, alcoholism and motivation.. PubMed.
323. Hechtman, L. (1991). Resilience and Vulnerability in Long Term Outcome of Attention Deficit Hyperactive Disorder. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674379103600606
324. Heilig, M. (2011). A WELCOME CHANGE THAT STOPS SHORT OF BEING FULLY SATISFYING. Addiction. https://doi.org/10.1111/j.1360-0443.2010.03233.x
325. Heilig, M. (2023). Stress‐related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective. Journal of Internal Medicine. https://doi.org/10.1111/joim.13636
326. Heilig, M., Egli, M., Crabbe, J. C., & Becker, H. C. (2010). Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2009.00194.x
327. Hemmingsen, R., Kramp, P., & Rafaelsen, O. J. (1983). Organic cerebral reactions in alcoholism: psychobiological aspects of treatment.. PubMed.
328. Henkin, R. I., & Abdelmeguid, M. (2020). Smell Loss and Onset of Phantosmia are Critical Aspects of Head Injury Cognition. The FASEB Journal. https://doi.org/10.1096/fasebj.2020.34.s1.02320
329. Henning, A., Kurtom, M., & Espiridion, E. D. (2019). A Case Study of Acute Stimulant-induced Psychosis. Cureus. https://doi.org/10.7759/cureus.4126
330. Hensley, P. L., & Clayton, P. J. (2013). Why the Bereavement Exclusion Was Introduced in <i>DSM-III</i>. Psychiatric Annals. https://doi.org/10.3928/00485713-20130605-04
331. Hernández, G., García, L. H., Baez, I. C., Rodrigo, A. M., Torres, C. D., Gómez-Juanes, R., & Pérez, P. G. (2023). Antiandrogenic treatment of obsessive compulsive neurosis: A case review. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1961
332. Hirano, S., Ichikawa, Y., Sato, B., Takefuji, Y., & Satoh, F. (2023). Successful treatment of myalgic encephalomyelitis/chronic fatigue syndrome using hydrogen gas: four case reports. Medical Gas Research. https://doi.org/10.4103/2045-9912.385441
333. Hirose, S. (2001). Restlessness related to SSRI withdrawal. Psychiatry and Clinical Neurosciences. https://doi.org/10.1046/j.1440-1819.2001.00789.x
334. Hirschfeld, R. M. A. (1996). Long-term drug treatment of unipolar depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199612000-00001
335. Hlodak, J., Gecková, A. M., Veselská, Z. D., & Feketeová, E. (2025). The burden of narcolepsy symptoms from patients’ perspective: a narrative qualitative study. Sleep And Breathing. https://doi.org/10.1007/s11325-025-03407-y
336. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
337. Hogarth, L. (2020). Addiction is driven by excessive goal-directed drug choice under negative affect: translational critique of habit and compulsion theory. Neuropsychopharmacology. https://doi.org/10.1038/s41386-020-0600-8
338. Hohmann, N., Mikus, G., & Czock, D. (2014). Effects and Risks Associated with Novel Psychoactive Substances. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2014.0139
339. Hokenson, R. E., Oijala, M., Short, A. K., Bolton, J. L., Chen, Y., Molet, J., Maras, P. M., Baram, T. Z., & Lür, G. (2020). Multiple Simultaneous Acute Stresses in Mice: Single or Repeated Induction. BIO-PROTOCOL. https://doi.org/10.21769/bioprotoc.3699
340. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
341. Housley, S. B., Patel, D., Nyabuto, E., & Reynolds, R. M. (2021). Spinal cord detethering without laminectomy or laminotomy. Surgical Neurology International. https://doi.org/10.25259/sni_942_2021
342. Howland, R. H. (2015). “I Want a New Drug”: Exercise as a Pharmacological Therapy. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20150727-03
343. Huang, K., & Tsai, S. (2012). The importance of measuring impulsiveness in patients with addiction problems. Journal of the Chinese Medical Association. https://doi.org/10.1016/j.jcma.2012.10.003
344. Hubbard, J. P., Everett, A., & Khan, M. A. (1996). Alcohol and Drug Abuse in Patients with Physical Disabilities. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952999609001655
345. Hurd, Y. L. (1996). Cocaine Effects on Dopamine and Opioid Peptide Neural Systems: Implications for Human Cocaine Abuse. PsycEXTRA Dataset. https://doi.org/10.1037/e495672006-006
346. Hybels, C. F., Blazer, D. G., & Steffens, D. C. (2006). Partial remission. A common outcome in older adults treated for major depression.. PubMed.
347. Ivlieva, N. Y. (2011). [Neurobiology of addictive behavior].. PubMed.
348. Jabeen, I., Venkataswamy, M., Sadaf, J., Reddy, M. N., Mallika, A. V. N., & Sushmitha, M. (2018). Drug Abuse, Addiction, its Causes and Treatment. Research Journal of Pharmaceutical Dosage Forms and Technology. https://doi.org/10.5958/0975-4377.2018.00038.1
349. Jaber, D., Awwa, I. A., & Wazaify, M. (2015). Multiple Prescription Drug Abuse and Salt Craving in a Psychotic Patient: A Case Report From a Teaching Hospital in Jordan. international journal high risk behaviors & addiction. https://doi.org/10.5812/ijhrba.22449v2
350. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
351. Jansen, K. (1990). Ketamine–Can Chronic Use Impair Memory. International Journal of the Addictions. https://doi.org/10.3109/10826089009056204
352. Jehanzeb, S., & Javaid, A. (2025). The Life-Changing Diagnosis in a Patient With Treatment-Resistant Depression, From Darkness to Light and Healing. BJPsych Open. https://doi.org/10.1192/bjo.2025.10735
353. Jeon, H. J. (2023). Clinical presentation, diagnosis, and treatment of sleep disorders in adolescents. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2023.66.4.258
354. Jevtovic, J., Jovanović, J., Grujicic, M. V. –., & Vujcic, J. (2021). OCCUPATIONAL STRESS IN COMPUTER OPERATORS. Knowledge International Journal.
355. Johnson, J., & Buisman‐Pijlman, F. (2016). Adversity impacting on oxytocin and behaviour: timing matters. Behavioural Pharmacology. https://doi.org/10.1097/fbp.0000000000000269
356. Johnston, M. P., & Coward, D. D. (2001). Cancer-Related Fatigue: Nursing Assessment and Management. AJN American Journal of Nursing. https://doi.org/10.1097/00000446-200104001-00005
357. Jonkers, C. C. (2009). Emotional support for chronically ill elderly persons : feasibility, effectiveness and cost-effectiveness of a minimal psychological intervention. https://doi.org/10.26481/dis.20090205cj
358. Jovanović, D., Todorović, Randjelović, S., & Kuśić, R. (1989). Acute poisoning by herbicide compounds.
359. Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Kloet, E. R. D., Fardet, L., Joëls, M., Leung, D. Y., McEwen, B. S., Roozendaal, B., Rossum, E. F. C. V., Ahn, J., Brown, D. W., Plitt, A., & Singh, G. (2014). Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13091264
360. Kachlík, P. (2019). Dědičnost závislostního chování a možnosti jeho včasného odhalování.
361. Kacir, C. D. (2010). The Evolutionary Bases of Substance Use and Abuse. Forum on public policy.
362. Kaggwa, M. M., Nkola, R., Najjuka, S. M., Bongomin, F., Ashaba, S., & Mamun, M. A. (2021). Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System. Risk Management and Healthcare Policy. https://doi.org/10.2147/rmhp.s314451
363. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
364. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
365. Kalsi, S. S., Wood, D. M., & Dargan, P. I. (2011). The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats Journal. https://doi.org/10.3402/ehtj.v4i0.7107
366. Kaminer, Y. (1992). Psychoactive Substance Abuse and Dependence as a Risk Factor in Adolescent‐Attempted and ‐Completed Suicide. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.1992.tb00003.x
367. Kane, J. M. (2011). Lurasidone. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.10075su1.05
368. Kanyengo, C. W. (2009). Zambia: The challenge of informing blind and deaf clients.
369. Karila, L., Lowenstein, W., Coscas, S., Benyamina, A., & Reynaud, M. (2009). [Complications of cocaine addiction].. PubMed.
370. Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H., & Lançon, C. (2014). Acute and Long-Term Effects of Cannabis Use: A Review. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990620
371. Karki, U., Girimaji, S. C., & Seshadri, S. (2019). Severe Recurrent Depressive Disorder with atypical features in a prepubertal child. Journal of Indian Association for Child and Adolescent Mental Health. https://doi.org/10.1177/0973134220190210
372. Kathula, P. (2020). Symptoms and Treatment of Depressive Disorders.
373. Kavanaugh, B. C., Dupont-Frechette, J. A., Jerskey, B. A., & Holler, K. (2016). Neurocognitive deficits in children and adolescents following maltreatment: Neurodevelopmental consequences and neuropsychological implications of traumatic stress. Applied Neuropsychology Child. https://doi.org/10.1080/21622965.2015.1079712
374. Kennedy, J. E., Jaffee, M. S., & Cooper, D. (2013). Posttraumatic Stress Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da08
375. Kerfoot, M. (2005). Partnerships between health and local authorities. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508441.003.0008
376. Khantzian, E. J. (1990). Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences.. PubMed.
377. Kim, E. K. E., & Beckmann, D. (2021). An adolescent with binge drinking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0027
378. Kintz, P., Villain, M., & Cirimele, V. (2008). Chemical Abuse in the Elderly: Evidence From Hair Analysis. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0b013e31816bac44
379. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
380. Kirkby, K. C. (2007). Recognising and Responding to Candidates' Health Needs. ACER Press eBooks.
381. Kitching, D. (2015). Depression in dementia. Australian Prescriber. https://doi.org/10.18773/austprescr.2015.071
382. Klaassen, T. (2021). Novel strategies to address disrupted sensing and signalling of satiety. https://doi.org/10.26481/dis.20210903tk
383. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2007.9.2/hkleber
384. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options.. PubMed.
385. Klega, A. E., & Keehbauch, J. (2018). Stimulant and Designer Drug Use: Primary Care Management.. PubMed.
386. Kloft, L., Monds, L. A., Blokland, A., Ramaekers, J. G., & Otgaar, H. (2021). Hazy memories in the courtroom: A review of alcohol and other drug effects on false memory and suggestibility. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2021.02.012
387. Knight, E., & McIntyre, A. (2012). Pharmacy medications and driving: delivering key information to ageing drivers.
388. Koenig, H. G. (1990). Depressed or Just Sick?-Reply. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1990.00390180147035
389. Kok, R., & Reynolds, C. F. (2017). Management of Depression in Older Adults. JAMA. https://doi.org/10.1001/jama.2017.5706
390. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
391. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
392. Koob, G. F. (2013). Neurocircuitry of Addiction: A brain reward deficit, stress surfeit and executive function disorder. Suchttherapie. https://doi.org/10.1055/s-0033-1351398
393. Koob, G. F. (2014). PL1 * ADDICTION AS A REWARD, STRESS AND EXECUTIVE FUNCTION DISORDER. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu051.1
394. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
395. Koob, G. F., Kandel, D. B., & Volkow, N. D. (2008). Pathophysiology of Addiction. Psychiatry. https://doi.org/10.1002/9780470515167.ch22
396. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
397. Kovich, H., Kim, W., & Quaste, A. M. (2023). Pharmacologic Treatment of Depression.. PubMed.
398. Koçak, Ö., & Koçak, S. (2023). Underrated Diagnosis: Prenatal Depression. Kafkas Journal of Medical Sciences. https://doi.org/10.5505/kjms.2023.21033
399. Kresina, T. F., Normand, J., Khalsa, J., Mitty, J. A., Flanigan, T., & Francis, H. (2004). Addressing the Need for Treatment Paradigms for Drug-Abusing Patients with Multiple Morbidities. Clinical Infectious Diseases. https://doi.org/10.1086/421403
400. Krishnan, J. (2024). MDMA (3,4-methylenedioxy-methamphetamine). BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/9789815223828124010004
401. Krüger, R. T. (2024). Addiction Disorders. Psychodrama in Counselling, Coaching and Education. https://doi.org/10.1007/978-981-99-7508-2_10
402. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
403. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
404. Kulkarni, H. (2020). Episodic, Event-triggered Staring Compulsion: An Unusual Form of Obsessive-compulsive Disorder. Indian Journal of Private Psychiatry. https://doi.org/10.5005/jp-journals-10067-0053
405. Kulkarni, S., Yeshaswini, M. C., & Durai, S. (2025). THYROID STORM OR STORM BREWING? A CASE OF LEVOTHYROXINE OVERDOSE WITH DELAYED PRESENTATION. International Journal of Scientific Research. https://doi.org/10.36106/ijsr/1509030
406. Kumar, J., Shaan, F., Naik, P. C., Reyazuddin, M., & Ahsan, M. N. (2025). Beyond the high: Exploring addiction to non-psychoactive substances. Archives of Biological Psychiatry. https://doi.org/10.25259/abp_16_2024
407. Kumar, P. S., Krishnan, A., & Suresh, R. (2019). Escitalopram-induced extrapyramidal symptoms. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_331_18
408. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
409. Kumari, D., & Kumar, P. (2023). Psychosocial Functioning of Females with Chronic Anxiety Disorder. Journal of Psychosocial Well-being. https://doi.org/10.55242/jpsw.2023.4107
410. Kumari, V. (2021). New insights on affective morbidity and childhood maltreatment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.121
411. Kusumadewi, A. F. (2021). Case Report: Magic Mushroom (Psilocybe Cubensis) Intoxication. Archives of The Medicine and Case Reports. https://doi.org/10.37275/amcr.v1i2.7
412. Kuypers, K. P. C. (2024). Microdosing psychedelics in the treatment of ADHD and comorbid disorders. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.44
413. Kuzminov, V. (2019). he dependence of the clinical picture of acute psychosis connected with alcohol withdrawal from the forms of alcohol consumption. Ukrains kyi Visnyk Psykhonevrolohii. https://doi.org/10.36927/2079-0325-v27-is1-2019-16
414. Kuzminov, V. (2021). The convulsive syndrome in the structure of alcohol withdrawal syndrome with delirium. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.969
415. Kyriazis, M. (2005). Clinical Anti-Aging Hormetic Strategies. Rejuvenation Research. https://doi.org/10.1089/rej.2005.8.96
416. Köroğlu, E., & Ayrıbaş, B. (2021). Prolonged post‐ECT delirium associated With substance‐induced psychosis: A case report. Perspectives In Psychiatric Care. https://doi.org/10.1111/ppc.12943
417. Lahey, B. B. (2021). Dimensions of Externalizing Problems. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197607909.003.0004
418. Laksmidewi, A. A. A. P., & Rau, C. P. V. (2021). Late Onset Alzheimer Dementia in Patients with Genotype E3/E4: A Case Report. Open Access Macedonian Journal of Medical Sciences. https://doi.org/10.3889/oamjms.2021.5583
419. Lambrey, S., Quilici, G., Bonnefoy, C., Rosier, A., & Guillin, O. (2009). Clozapine as an Antiagressive Agent in an Adolescent with Autism. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)71243-x
420. Lappin, J., & Sara, G. (2019). Psychostimulant use and the brain. Addiction. https://doi.org/10.1111/add.14708
421. Latt, N., Conigrave, K. M., Saunders, J. B., Marshall, E. J., & Nutt, D. (2009). Chapter 10 Other drugs. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199539338.003.0010
422. Lee, H., Kim, J., Lee, H.-S., Jo, Y.-H., Ko, J.-A., In, S., & Lee, J.-B. (2023). MS Fragmentation of ALD-52 with GC-MS and LC-QTOF. Korean Journal of Forensic Science. https://doi.org/10.53051/ksfs.2023.24.1.2
423. Lee, V. (2021). Mental Health Impacts during COVID-19. Journal of Anxiety & Depression. https://doi.org/10.46527/2582-3264.136
424. Lee, X.-C., Lu, T., Zheng, W., & Xue, Y. (2025). STRESS COMBINED WITH EXTINCTION PREVENTS COCAINE RELAPSE BY DISRUPTING MEMORY. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.175
425. Lehman, T. J. A. (2004). The Child Who Hurts All Over. https://doi.org/10.1093/oso/9780195157284.003.0004
426. Leikin, J. B. (2018). Toxicologic Malingering. CRC Press eBooks. https://doi.org/10.1201/9781351059633-8
427. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
428. Lervik, A., Haga, H. A., & Becker, M. (2010). Abnormal motor activity during anaesthesia in a dog: a case report. Acta veterinaria Scandinavica. https://doi.org/10.1186/1751-0147-52-64
429. Levy, T., Silver, H., Soufer, R., Rouhandeh, A., Kolevzon, A., Buxbaum, J. D., & Siper, P. M. (2025). Adolescents and adults with FOXP1 syndrome show high rates of anxiety and externalizing behaviors but not psychiatric decompensation or skill loss. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2025.1526383
430. Levy, T., Silver, H., Soufer, R., Rouhandeh, A., Kolevzon, A., Buxbaum, J. D., & Siper, P. M. (2025). Adolescents and adults with FOXP1 syndrome show high rates of anxiety and externalizing behaviors but not psychiatric decompensation or skill loss. medRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2025.01.04.24318923
431. Lhommée, E., Klinger, H., Thobois, S., Schmitt, E., Ardouin, C., Bichon, A., Kistner, A., Fraix, V., Xie, J., Kombo, M. A., Chabardès, S., Seigneuret, É., Benabid, A., Mertens, P., Polo, G., Carnicella, S., Quésada, J.-L., Bosson, J., Broussolle, E., ... Krack, P. (2012). Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain. https://doi.org/10.1093/brain/aws078
432. Li, K., & Loshak, H. (2019). Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines.
433. Li, Z., Goh, S. N., Teo, Y. W., & How, C. H. (2023). Management of intimate partner abuse. Singapore Medical Journal. https://doi.org/10.4103/singaporemedj.smj-2021-452
434. Lim, H., Cho, Y. S., & Kim, H. J. (2008). Case Reports : A Case of Gluteal Myonecrosis Aggravated after Discharge by Intoxication with Several Drugs Including Tricyclic Antidepressants (TCA). 대한응급의학회지.
435. Limandri, B. J. (2018). Benzodiazepine Use: The Underbelly of the Opioid Epidemic. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20180521-03
436. Lindenmayer, J., Khan, A., Harvey, P. D., Keefe, R. S., Liharska, L. E., Yavorsky, C., & Seddo, M. (2020). M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaa030.432
437. ling, Z. G. (2014). 脑瘫患儿家长焦虑和抑郁状况及其影响因素的研究. Zhonghua wuli yixue zazhi. https://doi.org/10.3760/cma.j.issn.0254-1424.2014.03.004
438. Linus, K. S. J., & Hutasoi, H. B. K. (2023). Penyembuhan dan Pencegahan pada Kecanduan Narkoba dan Zat Adiktif: Sebuah Tinjauan Pustaka. MAHESA Malahayati Health Student Journal. https://doi.org/10.33024/mahesa.v3i2.9273
439. Linzer, S., Chesir, A., Ginsburg, T., & Varas, O. (2017). Stressful Life Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190260859.003.0005
440. Lipsey, J. R. (2008). Electroconvulsive Therapy. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195309430.003.0029
441. Liu, Y., Deneen, K. M. V., Kobeissy, F., & Gold, M. S. (2010). Food Addiction and Obesity: Evidence from Bench to Bedside. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2010.10400686
442. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
443. Lockhart, P. J. (2001). Fetal alcohol spectrum disorders for mental health professionals - a brief review. Current Opinion in Psychiatry. https://doi.org/10.1097/00001504-200109000-00007
444. Logan, B. K., & Couper, F. J. (2003). 3,4-Methylenedioxymethamphetamine - Effects on Human Performance and Behavior.. PubMed.
445. Logožar, M. (2020). Depresija kao rizični čimbenik za školski uspjeh kod adolescenata.
446. Lovrečić, M., & Lovrečić, B. (2011). The most frequent psychopathology related to the use of 3,4-methylenedioxymethamphetamine (MDMA) of medical help seekers: causality or coincidence?. DOAJ (DOAJ: Directory of Open Access Journals).
447. Lucassen, P., Ligthart, S. A., Kramers, C., & Speckens, A. (2021). [Why do patients find it difficult to discontinue their medication?]. PubMed.
448. Ma, C., & Saluja, S. (2006). Pills for speedballing or cocaine dependence.
449. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
450. Maddocks, I., & Macleod, A. D. (2018). Sleep, sedation and coma. CRC Press eBooks. https://doi.org/10.4324/9781315385532-10
451. Madrid, P. A., Grant, R., Reilly, M. J., & Redlener, N. B. (2006). Challenges in Meeting Immediate Emotional Needs: Short-term Impact of a Major Disaster on Children's Mental Health: Building Resiliency in the Aftermath of Hurricane Katrina. PEDIATRICS. https://doi.org/10.1542/peds.2006-0099u
452. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
453. Majewska, M. (1996). Cocaine Addiction as a Neurological Disorder: Implications for Treatment. PsycEXTRA Dataset. https://doi.org/10.1037/e495672006-002
454. Majić, T., Brandt, L., & Montag, C. (2021). Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2021.2006372
455. Malaguarnera, M., Rodríguez‐Arias, M., & Miñarro, J. (2025). Neuroinflamación, estrés y consumo de drogas. Revista Española de Drogodependencias. https://doi.org/10.54108/10112
456. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
457. Mangot, A. G. (2014). Kleptomania: Beyond serotonin. Journal of Neurosciences in Rural Practice. https://doi.org/10.4103/0976-3147.145244
458. Mangum, A., Ling, D., & Velasquez, M. M. (2025). Substance Use Disorders. Social Work. https://doi.org/10.1093/obo/9780195389678-0342
459. Manschreck, T. C. (1996). Delusional disorder: the recognition and management of paranoia.. PubMed.
460. Marchesi, C., Tonna, M., & Maggini, C. (2008). Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. The World Journal of Biological Psychiatry. https://doi.org/10.1080/15622970701459828
461. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
462. Maricq, A., Jacques, D., Zdanowicz, N., Marchand, É., Evrard, P., Bulpa, P., & Reynaert, C. (2011). Duloxetine-related panic attacks.. Psychiatria Danubina.
463. Markham, R. A., & Watts, S. (2005). Etiology of Depression in Children.. Journal of instructional psychology.
464. Marković, H., Nikolac, N., Tripković, M., Haluga-Golubović, I., & Čustović, Z. (2012). Connection between Addictive Behavior and Investing on the Stock Market in Croatia.
465. Mast, R., Harper, B., Pollock, K., & Gentile, J. P. (2019). Pharmacologic Treatment of Attention Deficit Disorder in Children and Adolescents: Executive Function Agents, Stimulants, and Sympathomimetic Amines. Journal of Clinical Medicine and Therapeutics.
466. McAlister, S. (2019). Exploring the Trauma Experiences of Homeless Families: A Literature Synthesis.
467. McCabe, D., & Colbeck, M. (2015). The effectiveness of essential fatty acid, B vitamin, Vitamin C, magnesium and zinc supplementation for managing stress in women: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201513070-00010
468. McCabe, D., & Colbeck, M. (2015). The effectiveness of essential fatty acid, B vitamin, Vitamin C, magnesium and zinc supplementation for managing stress in women: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2015-2298
469. McFadden, K. M. (2010). Cross-Addiction: From Morbid Obesity to Substance Abuse. Bariatric Nursing and Surgical Patient Care. https://doi.org/10.1089/bar.2010.9922
470. McGorry, P. D., & Yung, A. R. (2020). Transition to adulthood. Routledge eBooks. https://doi.org/10.4324/9780429285806-2
471. McGorry, P. D., Purcell, R., Goldstone, S., & Amminger, G. P. (2011). Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e3283477a09
472. McGowan, K., March, K., & Finch, C. K. (2021). The Hunger for Mirtazapine: A Discontinuation Syndrome. Journal of Pain & Palliative Care Pharmacotherapy. https://doi.org/10.1080/15360288.2021.1883183
473. McIntosh, C., & Ritson, B. (2001). Treating depression complicated by substance misuse. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.7.5.357
474. McKenzie, B., Walker, T., & Chin, C. (2018). Prevalence of Burnout in Bahamian Health Care Personnel. Journal of Occupational and Environmental Medicine. https://doi.org/10.1097/jom.0000000000001383
475. Meena, D., Chand, S., & Kumar, D. (2019). A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS). Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v7i6.592
476. Mehdiratta, N., Kalita, S., & Hirsch, A. R. (2023). Generalized Restless Body Syndrome: A case of opioid withdrawal- induced restlessness extending beyond the legs. https://doi.org/10.14293/p2199-8442.1.sop-.ptttfx.v1
477. Mehendale, A. W., Goldman, M. P., Cizerle, K., & Parvin, T. L. (2016). The Problem of Outcomes in Addiction Treatments, the Inconvenient Truths. Journal of Addiction and Preventive Medicine.
478. Mendl, M., Burman, O. H. P., Laughlin, K. F., & Paul, E. S. (2001). Animal Memory and Animal Welfare. Animal Welfare. https://doi.org/10.1017/s0962728600023587
479. Menezes, M. C. D. C., Gonçalves, L. G. V., Chaves, S. C. D. S., Jaime, T. F. M., Oliveira, I. C. Z., Sobrinho, K. D. L., Oliveira, L. L. D., Araújo, J. V. L. D., Gurian, F. G., Soares, I. L. T., Nero, L. D., Pereira, P. H. D. O., Moraes, F. D. C., & Teixeira, G. P. (2023). MAIN CAUSES OF INTENTIONAL ACCIDENTS IN PEDIATRICS AND CLINICAL MANIFESTATIONS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593712308095
480. Menzel, J. E., & Thompson, J. K. (2010). Food Addiction. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0365
481. Mihaljević, S., Pavlović, M., Reine, K., & Čačić, M. (2020). THERAPEUTIC MECHANISMS OF KETAMINE. Psychiatria Danubina. https://doi.org/10.24869/psyd.2020.325
482. Mihaljević, S., Pavlović, M., Reiner, K., & Čačić, M. (2020). THERAPEUTIC MECHANISMS OF KETAMINE. https://doi.org/10.31219/osf.io/5xryf
483. Miles, N., Moyko, A., & Alao, A. K. (2013). 2202 – Stop and don’t smell the shoe polish. The use of inhalants among adolescents. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77075-5
484. Miller, A. (2018). Ritual abuse and mind control: the definition evolves. Routledge eBooks. https://doi.org/10.4324/9780429475467-2
485. Mistraletti, G., Donatelli, F., & Carli, F. (2005). Metabolic and endocrine effects of sedative agents. Current Opinion in Critical Care. https://doi.org/10.1097/01.ccx.0000166397.50517.1f
486. Miyasato, K. (2013). [Psychiatric and psychological features of nicotine dependence].. PubMed.
487. Moalla, M., Sellami, R., Baati, I., Féki, I., & Masmoudi, J. (2018). Persistent Psychosis with âEcstasyâ Single Use.
488. Moalla, M., Sellami, R., Baati, I., Féki, I., & Masmoudi, J. (2018). Persistent Psychosis with Ã¢Â€Â˜EcstasyÃ¢Â€Â™ Single Use.
489. Mohanty, I., Arunvikram, K., Sardar, K. K., Palai, S., Sahoo, G., & Patra, R. C. (2014). Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice. Veterinary World. https://doi.org/10.14202/vetworld.2014.299-305
490. Molero‐Chamizo, A. (2005). 3,4-metilenodioximetanfetamina (‘éxtasis’): efectos emocionales y cognitivos a largo plazo y depleción serotoninérgica. Revista de Neurología. https://doi.org/10.33588/rn.4102.2004547
491. Monteiro, M. I., Ferreira, A., Grebe, H., Gomes, L., & Costa, M. M. D. (2016). Psiquiátrico, aditivo ou orgânico:  um desafio nos adolescentes. DOAJ (DOAJ: Directory of Open Access Journals).
492. Montejo, Á. L., Montejo, L., & Baldwin, D. S. (2018). The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. https://doi.org/10.1002/wps.20509
493. Montgomery, S. (2006). Guidelines in major depressive disorder, and their limitations. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500600940492
494. Montgomery, S., Bebbington, P., Cowen, P. J., Deakin, J., Freeling, P., Hallström, C., Katona, C., King, D. S., Leonard, B., Levine, S., Phanjoo, A. L., Peet, M., Thompson, C. M., & Thompson, C. M. (1993). Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. Journal of Psychopharmacology. https://doi.org/10.1177/0269881193007001041
495. Montoya, A., & Alejandra, M. (2020). Estrés laboral y sus consecuencias en la salud que afectan el rendimiento.
496. Moorthi, K., Pertin, S., & Radhika, P. (2023). Homoeopathy for obsessive-compulsive disorder: A case report. Indian Journal of Research in Homoeopathy. https://doi.org/10.53945/2320-7094.1117
497. Moreau, J., Scherschlicht, R., Jenck, F., & Martin, J. R. (1995). Chronic mild stress-induced anhedonia model of depression. Behavioural Pharmacology. https://doi.org/10.1097/00008877-199511000-00003
498. Morrigan, C. (2017). Failure to Comply: Madness and/as Testimony. Canadian Journal of Disability Studies. https://doi.org/10.15353/cjds.v6i3.366
499. Moshé, S. L., & Galanopoulou, A. S. (2018). Commentary on Schotte et al. “Development of temporal lobe epilepsy during maintenance electroconvulsive therapy: A case of human kindling?”. Epilepsia Open. https://doi.org/10.1002/epi4.12296
500. Mostafavi, S., & Bidaki, R. (2015). Priapism Followed by Discontinuation of Methadone: A rare Case Report.. DOAJ (DOAJ: Directory of Open Access Journals).
501. Moukaddam, N., & Shah, A. A. (2016). Treatment-Resistant Depression: An Overview. Psychiatric Annals. https://doi.org/10.3928/00485713-20160215-01
502. Mude, G., Pise, S., Makade, K., Fating, R., & Wakodkar, S. (2021). Termiticidal Activity of Ethanolic and n- Hexane Leaf Extraction of Calotropis procera, Cannabis indica and Mentha longifolia Against a Higher Termite Microtomes obesi. Journal of Developing Drugs. https://doi.org/10.35248/2329-6631.21.10.206
503. Mukherjee, S., Ghosh, P., Perti, A., Mushthi, D., Prakash, J., & Kulkarni, S. (2025). Varied Outcomes of Prolonged Delirium Tremens – A Case Series. Medical Journal of Dr D Y Patil Vidyapeeth. https://doi.org/10.4103/mjdrdypu.mjdrdypu_170_24
504. Mula, M., Matteo, P., Basaglia, C., Favaretto, E., & Schwitzer, J. (2013). 2804 – Asenapine after clozapine: is possible?. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77392-9
505. Muliyala, K. P., Lima, C. A. D. M., & Chong, D. (2024). S9: Addictions in Later Life an Emerging Crisis. International Psychogeriatrics. https://doi.org/10.1017/s104161022400111x
506. Mullen, S. (2018). Major depressive disorder in children and adolescents. Mental Health Clinician. https://doi.org/10.9740/mhc.2018.11.275
507. Muncie, H. L., Yasinian, Y., & Oge, L. K. (2013). Outpatient management of alcohol withdrawal syndrome.. PubMed.
508. Muneer, A. (2016). Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach. Korean Journal of Family Medicine. https://doi.org/10.4082/kjfm.2016.37.3.137
509. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
510. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
511. Murray, R. B. (1996). Stressors and Coping Strategies of Homeless Men. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/0279-3695-19960801-13
512. Musalek, M. (2013). Reduction of harmful consumption versus total abstinence in addiction treatment. Neuropsychiatry. https://doi.org/10.2217/npy.13.84
513. Mushthi, D., Chakraborty, R., Chaudhury, S., & Singh, A. (2025). Olanzapine-induced akathisia treated with clozapine. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_268_24
514. Musálek, M. (2011). Pathologisches Spielen: Impulskontrollstörung oder Sucht?. Suchttherapie. https://doi.org/10.1055/s-0031-1284655
515. Möller, H. (2010). Agomelatine: relief ensured at each and every stage of depression. Annals of General Psychiatry. https://doi.org/10.1186/1744-859x-9-s1-s49
516. Möller, H., Demyttenaere, K., Sacchetti, E., Rush, A. J., & Montgomery, S. (2003). Improving the chance of recovery from the short- and long-term consequences of depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200307000-00004
517. Müller, C. P. (2013). Episodic Memories and Their Relevance for Psychoactive Drug Use and Addiction. Frontiers in Behavioral Neuroscience. https://doi.org/10.3389/fnbeh.2013.00034
518. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
519. Nachane, H., & Nayak, A. (2020). Acute dystonic reaction due to a combination of chloroquine and doxycycline in an emergency psychiatry setting. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_712_19
520. Nahas-Vigon, J. H., & Fingerhood, M. (2025). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0005
521. Naidu, S., Bibat, G., Lin, D., Burger, P. C., Barker, P. B., Rosemberg, S., Braverman, N., Arroyo, H., Dowling, M. M., Hamosh, A., Kimonis, V., Blank, C., Fiumara, A., Facchini, S., Singhal, B., Moser, H. W., Kelley, R. I., & DiMauro, S. (2005). Progressive cavitating leukoencephalopathy: A novel childhood disease. Annals of Neurology. https://doi.org/10.1002/ana.20671
522. Nayak, R. D. (2015). Internet Addiction a Comparative Study between Undergraduate Students of India and Malaysia. International Journal of Indian Psychology. https://doi.org/10.25215/0204.088
523. Nazlı, Ş. B., & Sevindik, M. (2020). Use of methylphenidate in co-existing major depression and loss of libido and erectile dysfunction: a case report. Anatolian Journal of Psychiatry. https://doi.org/10.5455/apd.112405
524. Neavins, T. M., Easton, C. J., Brotchie, J., & Carroll, K. M. (2008). Empirically validated psychological therapies for drug dependence. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544392.020
525. Negro, A., Rocchietti-March, M., Fiorillo, M., & Martelletti, P. (2011). Chronic migraine: current concepts and ongoing treatments.. PubMed.
526. Nehretskii, S. (2023). Interdisciplinary Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Study of Abuse of Psychoactive Substances. SSP Modern Pharmacy and Medicine. https://doi.org/10.53933/sspmpm.v3i1.85
527. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
528. Nicholi, A. M. (1984). The Nonmedical use of Amphetamines among the College Age Group: Recent Research Concerning Epidemiology and Toxicity. Journal of American College Health. https://doi.org/10.1080/07448481.1984.9939592
529. Niesink, R. J., & Laar, M. V. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC?. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2013.00130
530. Nightall, C. (2018). Emotional reactions to serious diagnosis. Routledge eBooks. https://doi.org/10.4324/9780429474033-3
531. Nilaweera, D., Freak‐Poli, R., & Ryan, J. (2019). The impact of psychological stress and trauma on later-life cognitive function and dementia.
532. Noel, N., Seibell, P., Nadeau, J., & Storch, E. (2016). Treating just-right symptoms in geriatric obsessive-compulsive disorder. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196700
533. Noor, T., Shakil, A., Khan, A. W., Zaidi, S. M. F., Rangwala, H. S., & Rangwala, B. S. (2023). Psilocybin therapy: A novel approach to treating depression. International Journal of Surgery Global Health. https://doi.org/10.1097/gh9.0000000000000175
534. Ns, M., & Gold, M. S. (1990). The contemporary alcoholic.. PubMed.
535. Nunes, E. V., Deliyannides, D. A., Donovan, S. J., & McGrath, P. J. (1996). THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS. Psychiatric Clinics of North America. https://doi.org/10.1016/s0193-953x(05)70290-2
536. Nutt, D., & Nestor, L. J. (2018). Key elements of addiction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198797746.003.0003
537. O'Donohoe, A., Burgess, C., & Gill, M. (2000). Agony and ecstasy: a review of MDMA effects and toxicity. European Psychiatry. https://doi.org/10.1016/s0924-9338(00)00396-5
538. Ochoa, A., Corgo, S. R., Pey, M. A., Cristobal, M., Vicente, E. P., Campos, A., Gordillo, C., Ibañez, A. C. C., Astorga, A. Á., & Huelva, P. A. (2023). Chronic disease (CD) during transition from child to adult.Psychopathological consequences and coping strategies. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1565
539. Oh, S.-H. (2019). 12 - CAN RORSCHACH DIFFERENTIATE BIPOLAR DISORDER FROM DEPRESSIVE DISORDER? : COMPARISON OF RORSCHACH SCORES BETWEEN BIPOAR DEPRESSION AND UNIPOLAR DEPRESSION. https://doi.org/10.26226/morressier.5d1a038757558b317a13f97e
540. Oikawa, S. Y., Holloway, T. M., & Phillips, S. M. (2019). The Impact of Step Reduction on Muscle Health in Aging: Protein and Exercise as Countermeasures. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2019.00075
541. Olesen, A. S., & Jensen, O. H. (2006). [Pain centers--why and when?].. Ugeskrift for Læger.
542. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
543. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
544. Oluwole, L., Dada, M. U., & Obadeji, A. (2013). Self-inflicted bilateral orchidectomy precipitated by erotic bizarredelusions : a case report : scientific letters. African Journal of Psychiatry.
545. Omari, F. E., Berrada, H., Chebli, H., & Azraf, F. (2023). Depressive disorder comorbid with problematic alcohol use. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1374
546. Onda, K., Yukawa, T., Sakaue, M., Tsuboya, R., Inoue, E., & Someya, T. (2021). Withdrawal from long‐term use of caffeinated drinks can cause schizophrenia‐like symptoms: A case report. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13199
547. Ori, Y., & Solun, B. (2011). Severe hiccups associated with intra-articular corticosteroid injection — A case report. Open Medicine. https://doi.org/10.2478/s11536-011-0105-2
548. Osborn, C. J., & Iarussi, M. M. (2017). Addictions Counseling. Routledge eBooks. https://doi.org/10.4324/9781315537061-13
549. Oster, E., Čudina, N., Pavasović, H., Crnić, A. P., Božić, F., Fadel, C., & Gıorgı, M. (2023). Intoxication of dogs and cats with common stimulating, hallucinogenic and dissociative recreational drugs. Veterinary and Animal Science. https://doi.org/10.1016/j.vas.2023.100288
550. Otte, C. (2008). Incomplete remission in depression: role of psychiatric and somatic comorbidity. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.4/cotte
551. Oughli, H. A. (2022). Resilience and mind-body interventions in late-life depression. Current psychiatry. https://doi.org/10.12788/cp.0308
552. Outhoff, K. (2019). Depression in doctors: A bitter pill to swallow. South African Family Practice. https://doi.org/10.4102/safp.v61i1.5046
553. O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence.. PubMed.
554. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
555. Page, R. D. (1983). Cerebral dysfunction associated with alcohol consumption.. PubMed.
556. Pai, N., & Vella, S. (2011). Reason for clozapine cessation. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2011.01776.x
557. Pal, H., Kumar, R., Bhushan, S., & Berry, N. (2005). Psychiatric co-morbidity associated with pheniramine abuse and dependence. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.46079
558. Palijan, T. Ž., Kovačević, D., & Turcinović, M. K. (2007). Psychodynamic Characteristics of Ego in Alcoholic Offenders and Non-Offenders. Alcoholism Clinical and Experimental Research.
559. Panahi, S., & Tremblay, A. (2018). Sedentariness and Health: Is Sedentary Behavior More Than Just Physical Inactivity?. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2018.00258
560. Pang, N. T. P., & Masiran, R. (2020). Mood disorder induced by prednisolone – an easily overlooked complication. Current Problems of Psychiatry. https://doi.org/10.2478/cpp-2020-0012
561. Paraschakis, A., & Konstantinidou, D. (2012). P-664 - Stalking of psychiatrists by their patients: an unsettling reality. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74831-9
562. Parekh, V. (2019). Psychoactive drugs and driving. Australian Prescriber. https://doi.org/10.18773/austprescr.2019.070
563. Parker, G., & Manicavasagar, V. (2005). Chronic stress-related non-melancholic depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544194.016
564. Parolaro, D., Viganò, D., & Rubino, T. (2005). Endocannabinoids and Drug Dependence. Current Drug Targets - CNS & Neurological Disorders. https://doi.org/10.2174/156800705774933014
565. Parrott, A. C. (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.351
566. Parrott, A. C. (2005). Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105048900
567. Parrott, A. C. (2006). MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Journal of Psychopharmacology. https://doi.org/10.1177/0269881106063268
568. Parsa, A., Mohammadkhan, A., & Babaeian, M. (2017). Zolpidem-Induced Narcolepsy, Faint, Seizure or Coma? A Case Report. Case Reports in Clinical Medicine. https://doi.org/10.4236/crcm.2017.62004
569. Pary, R., Lippmann, S., & Tobias, C. R. (1988). Depression and Alcoholism: Clinical Considerations in Management. Southern Medical Journal. https://doi.org/10.1097/00007611-198812000-00016
570. Patel, A., Moreland, T., Haq, F., Siddiqui, F., Mikul, M., Qadir, H., & Raza, S. (2011). Persistent Psychosis After a Single Ingestion of “Ecstasy” (MDMA). The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01200
571. Paul, M. A., & Teli, B. A. (2020). ADHD and Substance Abuse in Children and Adolescents. Advances in medical diagnosis, treatment, and care (AMDTC) book series. https://doi.org/10.4018/978-1-7998-5495-1.ch014
572. Paul, M., Paul, P., Dey, D., Bhardwaj, A. K., & Paul, K. (2021). A Case of Spontaneous Pneumomediastinum Following Ecstasy and Marijuana Use. Cureus. https://doi.org/10.7759/cureus.15871
573. Paykel, E. S. (2001). Continuation and maintenance therapy in depression. British Medical Bulletin. https://doi.org/10.1093/bmb/57.1.145
574. Peele, S. (2001). Is Gambling an Addiction Like Drug and Alcohol Addiction?: Developing Realistic and Useful Conceptions of Compulsive Gambling. Journal of Gambling Issues. https://doi.org/10.4309/jgi.2001.3.2
575. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
576. Peniston, J. H. (2012). A Review of Pharmacotherapy for Chronic Low Back Pain with Considerations for Sports Medicine. The Physician and Sportsmedicine. https://doi.org/10.3810/psm.2012.11.1985
577. Penn, M., & Goldstein, D. (2005). The Role of Hunger and Satiety in Weight Management. Humana Press eBooks. https://doi.org/10.1385/1-59259-865-x:307
578. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
579. Pervanidou, P., & Chrousos, G. P. (2018). Early-Life Stress: From Neuroendocrine Mechanisms to Stress-Related Disorders. Hormone Research in Paediatrics. https://doi.org/10.1159/000488468
580. Perłowski, J., Miśkiewicz, M., Ptak, J., Noga, R., Teska, V., Marcinkowska, J., Herc, A., Koczkodon, K., Sawczuk, M., & Krompiewski, M. (2024). Recreational ketamine use and its impact on health. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.68.55185
581. Peven, J. C., Stillman, C. M., & Erickson, K. I. (2019). The Influence of Physical Exercise on Cognitive Aging. Cambridge University Press eBooks. https://doi.org/10.1017/9781108554350.016
582. Phillips, M. M. (1990). The Alcohol Drinking History.
583. Piazza, P. V., & Deroche‐Gamonet, V. (2013). A multistep general theory of transition to addiction. Psychopharmacology. https://doi.org/10.1007/s00213-013-3224-4
584. Pikirenia, U., Fedotov, I., Tuchina, O., & Kapytau, A. U. (2017). Cognitive impairment due to alcohol abuse: current status of research. Vestnik of Saint Petersburg University Medicine. https://doi.org/10.21638/11701/spbu11.2017.306
585. Pimiento, A. P., Parra, B. F., Montoya, M. S., Arranz, S., & Domínguez, A. R. (2001). Síndrome de anafilaxia inducida por ejercicio. Anales de Medicina Interna. https://doi.org/10.4321/s0212-71992001000500010
586. Pina, I. B., Gorostiza, P. R., Yllán, P. V., & Fernández, J. V. (2000). [Persisting and late onset psychotic disorder due to consumption of ecstasy (MDMA)].. PubMed.
587. Pineda, I. I., Espadas, M. L., Chamorro, M. V., & Alda-Diez, J. A. (2018). Efectos secundarios del metilfenidato en población infantil y juvenil. Revista de Neurología. https://doi.org/10.33588/rn.6605.2017480
588. Pitel, A., & Segobin, S. (2023). Contribution of Thalamocortical Loops to the Development, Persistence, and Complications of Alcohol Use Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197676158.003.0069
589. Piwuna, C. G., Makput, D. M., & Wakil, M. A. (2015). Persistent delusional disorder in a 32 year old male. Highland Medical Research Journal.
590. Poirier, M. F., & Ginestet, D. (1995). [Drugs diverted from reaching drug addicts].. PubMed.
591. Pollack, M. H. (2001). Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder.. PubMed.
592. Popescu, E.-C., & Pușcaș, C. (2018). Episod psihotic acut indus de sertralină la un pacient cu tulburare obsesiv-compulsivă şi tulburare anxios-fobică. Psihiatru ro.
593. Popescu, E.-C., & Pușcaș, C. (2018). Sertraline induced psychosis in a patient with obsessive compulsive disorder (OCD) and anxiety disorder. Psihiatru ro. https://doi.org/10.26416/psih.54.3.2018.1917
594. Porche, M. V., Koslouski, J. B., & Oblath, R. (2020). Trauma Disorders in Adolescence. The Encyclopedia of Child and Adolescent Development. https://doi.org/10.1002/9781119171492.wecad451
595. Portenoy, R. K., & Bruera, É. (2003). Clinical Trials of Antiemetics in the Palliative Care Setting: Research Issues. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780195130652.003.0005
596. Porter, T., & Feldman, M. D. (2011). A Case of Factitious Pedophilia. Journal of Forensic Sciences. https://doi.org/10.1111/j.1556-4029.2011.01804.x
597. Potocka‐Banaś, B., Majdanik, S., Korwin-Piotrowska, K., Dembińska, T., Janus, T., & Borowiak, K. (2013). [Overdosing of popular medicines available without a prescription, a new trend among teenagers].. PubMed.
598. Pounder, D. J., Karch, S. B., & Stephens, B. G. (1998). Acute excited states and sudden death. BMJ. https://doi.org/10.1136/bmj.316.7138.1171
599. Prabha, Y. S. (2023). Stress as a Topic of Concern in Gut Health: A Review. UTTAR PRADESH JOURNAL OF ZOOLOGY. https://doi.org/10.56557/upjoz/2023/v44i123527
600. Prathima, P. R., Johnson, D. B., Suresh, R., Venkatnarayanan, R., & Ahammad, P. M. A. (2013). Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route. Research Journal of Pharmacology and Pharmacodynamics.
601. Preuss, U. W., Wong, W., & Farren, C. K. (2014). Chapter 9: Bipolar Affective Disorders and Alcohol Dependence: Comorbidity, Consequences Consequences, and Treatment.
602. Proczkowska‐Björklund, M., Gustafsson, P., & Svedin, C. G. (2010). Children’s play after anaesthesia and surgery: background factors and associations to behaviour during anaesthetic induction. Journal of Child Health Care. https://doi.org/10.1177/1367493509359225
603. Prusiński, A. (1999). [Insomnia and its treatment].. PubMed.
604. Prévot, T. D. (2015). Pathogénicité du stress chronique chez l'adulte dans un modèle murin : impact à long terme et rôle de la somatostatine.
605. Punukula, H. C., Sree, B. K., & Pratyusha, V. (2020). Safety and Efficacy of Ketamine in Treatment-Resistant Depression (TRD). International Journal of Pharmaceutical Sciences Review and Research. https://doi.org/10.47583/ijpsrr.2020.v64i02.029
606. Pérez, J. M. C., & Orellana, G. (2007). [Update in the clinic of addictions: learning and dopamine].. PubMed.
607. Păunica, S., Giurgiu, M., Vasilache, A., Păunică, I., Motofei, I. G., Vasilache, A., Dumitriu, H., & Dumitriu, A. S. (2016). Finasteride adverse effects and post-finasteride syndrome; implications for dentists. Journal of Mind and Medical Sciences. https://doi.org/10.22543/2392-7674.1039
608. Płytycz, B., & Seljelid, R. (2002). Stress and immunity: minireview.. PubMed.
609. Queiroz, A. P. D. S., Pedro, M. O. P., Campos, M. W., Torales, J., Ventriglio, A., & Castaldelli-Maia, J. M. (2025). Cognitive Effects of Cannabis Use: A Comprehensive Review Across Domains. Neurology International. https://doi.org/10.3390/neurolint17070107
610. Radhakrishnan, R., Wilkinson, S. T., & Dâ€TMSouza, D. C. (2014). Gone to Pot â€“ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2014.00054
611. Radmanović, M. B., & Burgić, S.-S. (2020). Comorbidity in Children and Adolescents with ADHD. IntechOpen eBooks. https://doi.org/10.5772/intechopen.94527
612. Rahmani, M., Ahmadi, S., & Moghaddam, H. H. (2011). Serotonin Syndrome Following Single Ingestion of High Dose.
613. Rajesh, M., & Kumar, C. P. G. (2014). Influence of interactional relationship on stress among women executives in software company in Chennai. EXCEL International Journal of Multidisciplinary Management Studies.
614. Raju, V., & Muthulakshmi, G. (2014). Impact of stress in work life balance among working people. South Asian Journal of Marketing & Management Research.
615. Rakofsky, J. J., & Dunlop, B. W. (2014). Treating Bipolar Mania in the Outpatient Setting: Enlist the Help of Family, Employ Evidence-Based Pharmacologic and Psychotherapeutic Strategies. Current psychiatry.
616. Ramesh, D., Schlosburg, J. E., Wiebelhaus, J. M., & Lichtman, A. H. (2011). Marijuana Dependence: Not Just Smoke and Mirrors. ILAR Journal. https://doi.org/10.1093/ilar.52.3.295
617. Ranganathan, A., & Beitman, B. D. (1998). Panic disorder: a different perspective.. PubMed.
618. Rani, S., & Saini, D. S. (2015). Organizational Stress in Relation to Job Satisfaction and General Health of Professional Women. International journal of education and management studies.
619. Rao, T. S. (2018). Psychosocial therapies in addictive disorders. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.224346
620. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
621. Rasmussen, K. G., & Ritter, M. J. (2014). Some Considerations of the Tolerability of Ketamine for ECT Anesthesia. Journal of Ect. https://doi.org/10.1097/yct.0000000000000100
622. Rastegar, D. A., & Fingerhood, M. (2015). Cocaine, Methamphetamine, and Other Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0008
623. Rastegar, D. A., & Fingerhood, M. (2015). Marijuana and Other Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0010
624. Ree, J. M. V., Koob, G. F., Higgins, G. A., Naranjo, C. A., & Zvartau, E. (1995). Neurohormonal Systems Underlying Drug Addiction: Relevance for Treatment Strategies. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7218-8_27
625. Regnard, C., Kindlen, M., & Nichol, T. (2018). Helping the anxious person. CRC Press eBooks. https://doi.org/10.1201/9781315376363-29
626. Rengifo, C. A. (2014). Estudio de caso: Trastorno Obsesivo-Compulsivo. Revista de Investigación Universitaria. https://doi.org/10.17162/riu.v3i2.519
627. Resen, K., Pagsberg, A. K., & Jörgens, G. (2014). [Atomoxetine for treatment of children and adolescents with ADHD].. PubMed.
628. Riaz, A., Shahid, Q., Yousaf, H. M., Gul, U., Shah, S. S., Hidayat, A., Hamid, T., Rahman, A. U., Usman, M., Khan, M. K., Muhtiar, R., & Khalid, B. (2024). Mirtazapine in Primary Insomnia: Case report and Literature review. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2024.23.1.2213
629. Riccio, C. A., Pliego, J., & Rae, W. A. (2016). Mind-body approaches and chronic illness: Status of research. International Journal of School & Educational Psychology. https://doi.org/10.1080/21683603.2016.1130544
630. Rickels, K., & Downing, R. (2024). Nonspecific Factors and Drug and Placebo Response in Psychiatry. Routledge eBooks. https://doi.org/10.4324/9781032632841-20
631. Riddle, M. A., King, R. A., Hardin, M. T., Scahill, L. D., Ort, S. I., Chappell, P., Rasmusson, A. M., & Leckman, J. F. (1990). Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.1990.1.193
632. Riley, M. A., Ahmed, S., & Locke, A. (2016). Common Questions About Oppositional Defiant Disorder.. PubMed.
633. Riva, A., Castelao-Almodóvar, S., Quintana, R., Artigas, A. A., & Soriano, B. (2023). Post-COVID syndrome or persistent COVID and depression. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1708
634. Rivas-Vazquez, R. A., Carrazana, E., Rey, G., & Wheeler, S. D. (2000). SELECTIVE SEROTONIN REUPTAKE INHIBITOR DISCONTINUATION SYNDROME: THREE CASES PRESENTING TO A NEUROLOGIC PRACTICE. The Neurologist. https://doi.org/10.1097/00127893-200006060-00005
635. Rizwana, S. R. S., Josna, T. J. T., & G.V.Nagaraju, G. (2019). CASE STUDY ON DEPRESSION. International Journal of Indigenous Herbs and Drugs.
636. Robertson, S., Peacock, E. E., & Scott, R. M. (2023). Benzodiazepine Use Disorder: Common Questions and Answers.. PubMed.
637. Rodriguez, C. P., Dodds, T., & Suzuki, J. (2017). Addiction. Pain Medicine. https://doi.org/10.1007/978-3-319-43133-8_33
638. Roh, H. S., Park, B. R., Jang, E. Y., Kim, J. S., & Gwak, Y. S. (2018). Acupuncture on the Stress-Related Drug Relapse to Seeking. Evidence-based Complementary and Alternative Medicine. https://doi.org/10.1155/2018/5367864
639. Rollin‐Sillaire, A., Delbeuck, X., Pollet, M., Mackowiak, M., Lenfant, P., Noël, M., Façon, T., Leleu, X., Pasquier, F., & Rhun, É. L. (2013). Memory loss during lenalidomide treatment: a report on two cases. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-14-41
640. Romero‐Sandoval, E. A. (2011). Depression and Pain. Anesthesiology. https://doi.org/10.1097/aln.0b013e31822ec185
641. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
642. Roques, B. (2000). La dangerosité des drogues : mécanismes neurobiologiques des addictions et approches thérapeutiques.. médecine/sciences. https://doi.org/10.4267/10608/1588
643. Rosentreter, A., Dietlein, T. S., & Lappas, A. (2016). Umsetzung und Schwierigkeiten bei Tropftherapien – der ältere Glaukompatient im Fokus. Klinische Monatsblätter für Augenheilkunde. https://doi.org/10.1055/s-0041-110447
644. Rotunda, R. J., Herzog, J. R., Dillard, D. R., King, E., & Wilson, K. O. (2024). Alcohol Misuse and Correlates with Mental Health Indicators among Firefighters. Substance Use & Misuse. https://doi.org/10.1080/10826084.2024.2422975
645. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
646. Rybárová, V., Kumicikova, I., Novomeský, F., Straka, Ľ., Krajčovič, J., & Janík, M. (2021). Ecstasy-Induced Malignant Hyperthermia with Fatal Outcome: A Case Report. Acta Medica Martiniana. https://doi.org/10.2478/acm-2021-0004
647. Sadikin, A., & Linda, N. (2018). PENYALAHGUNAAN NARKOBA DAN PSIKOTROPIKA DI KALANGAN REMAJA.
648. Saini, S., Shandil, A., & S.K., E. (2012). Recent Therapies in Depression. InTech eBooks. https://doi.org/10.5772/33335
649. Salaam, A. O. (2005). Contributions of negative reinforcement processes to compulsive drug use. IFE PsychologIA. https://doi.org/10.4314/ifep.v13i2.23686
650. Salani, D., Goldin, D., Valdes, B., & Santis, J. P. D. (2023). The Price of Gambling: Examining Gambling Disorders. Issues in Mental Health Nursing. https://doi.org/10.1080/01612840.2023.2232862
651. Salman, S., Abdullah, A., Idrees, J., & Shah, F. H. (2016). How Community Pharmacists can Help Patients on Antidepressants at Risk for Suicides and Sexual Dysfunction. Journal of Pharmacy Practice and Community Medicine. https://doi.org/10.5530/jppcm.2016.3.8
652. Sanchis‐Segura, C., & Spanagel, R. (2006). REVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2006.00012.x
653. Santambrogio, A. (2016). Psicofarmaci e vita quotidiana. SALUTE E SOCIETÀ. https://doi.org/10.3280/ses2016-003012
654. Santos, G., Lima, C. A., & Vitória, J. (2016). Alcohol use disorder following traumatic brain injury: Lessons learned from bench to bedside. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1080
655. Sarkar, S., & Dinesh, M. (2023). The threshold problem of impairment criteria in psychiatric diagnosis. Journal of SAARC Psychiatric Federation. https://doi.org/10.4103/jspf.jspf_12_23
656. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
657. Sarris, J., O’Neil, A., Coulson, C., Schweitzer, I., & Berk, M. (2014). Lifestyle medicine for depression. BMC Psychiatry. https://doi.org/10.1186/1471-244x-14-107
658. Sayyah, M., Majzoob, S., & Sayyah, M. (2013). Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2013.783011
659. Schepis, T. S., Rao, U., Yadav, H., & Adinoff, B. (2011). The Limbic-Hypothalamic-Pituitary-Adrenal Axis and the Development of Alcohol Use Disorders in Youth. Alcoholism Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2010.01380.x
660. Schneier, F. R., Bruce, L. C., & Heimberg, R. G. (2014). Social Anxiety Disorder (Social Phobia). American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg18
661. Schneir, A., & Clark, R. F. (2007). The Role of Illicit Drug Use in Sudden In-Custody Death. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-015-7_6
662. Schuckit, M. A. (1996). Alcohol, Anxiety, and Depressive Disorders.. PubMed.
663. Schulman, E. A. (2011). Abuse and Maltreatment: Their Effect on Headache. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2011.02020.x
664. Schwabe, L., Dickinson, A., & Wolf, O. T. (2011). Stress, habits, and drug addiction: A psychoneuroendocrinological perspective.. Experimental and Clinical Psychopharmacology. https://doi.org/10.1037/a0022212
665. Schwartz, R. H. (1984). Psychoactive Drug Use During Adolescence: The Pediatrician's Role. Archives of Pediatrics and Adolescent Medicine. https://doi.org/10.1001/archpedi.1984.02140400083021
666. Schwerthöffer, D., Fatke, B., & Förstl, H. (2020). Dilemmasituation: Nächtlicher Unruhezustand beim älteren Patienten.
667. Scoppetta, M., Gennaro, G. D., & Scoppetta, C. (2006). Selective serotonine reuptake inhibitors prevents emotional lability in healthy subjects.. PubMed.
668. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
669. Sellami, R., Messedi, N., Féki, I., Baâti, I., Zahaf, A., & Masmoudi, J. (2016). Zolpidem abuse: About a case. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1056
670. Sengupta, R., Roy, S., & Bhattacharya, M. (2019). STUDY OF GENE-ENVIRONMENT CAUSES OF MAJOR DEPRESSIVE DISORDER TO STATISTICALLY DEFINE THE MOST COMMON CAUSE BEHIND IT.. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/8804
671. Shahrokh, B. (2017). None. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.3.3
672. Shahrokh, B. E. K. (2017). Acute Versus Long-Term Care Strategies for Individuals in Treatment for Substance Use Disorders. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/ofoaj.2017.03.555611
673. Shahrokh, B. E. K. (2017). Acute Versus Long-Term Care Strategies for Individuals in Treatment for Substance Use Disorders. Psychology and Behavioral Science International Journal. https://doi.org/10.19080/pbsij.2017.03.555611
674. Shamsi, S., & Khan, S. (2019). Use of Pain Assessment Tools in Physiotherapy.
675. Shaner, J. W. (2002). Caries associated with methamphetamine abuse.. PubMed.
676. Shanmugasundaram, N., Nivedhya, J., Karthik, M. S., & Sathianathan, R. (2019). Risperidone-induced retrograde ejaculation and lurasidone may be the alternative. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_8_19
677. Sharif, A. T. (2018). Effect of Stress on Academic Performance of Undergraduate Medical Students.
678. Sharma, S., Nepal, B., Moon, C. S., Chabenne, A., Khogali, A., Ojo, C., Hong, E., Gaudet, R., Sayed-Ahmad, A., Jacob, A., Murtuza, M., & Firlit, M. L. (2014). Psychology of Craving. Open Journal of Medical Psychology. https://doi.org/10.4236/ojmp.2014.32015
679. Shelton, R. C. (2009). Long-Term Management of Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.8133su1c.05
680. Sherman, D. S. (1988). Psychoactive Drug Misuse in Long-Term Care: Some Contributing Factors. Journal of Pharmacy Practice. https://doi.org/10.1177/089719008800100307
681. Shiffman, S., West, R., & Gilbert, D. G. (2004). Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine & Tobacco Research. https://doi.org/10.1080/14622200410001734067
682. Shinohara, R. C., Oshima, T., Otsubo, T., Ariga, K., Ono, T., Muneoka, K., Umezu, H., & Mikami, N. (2024). Successful utilization of clozapine for a patient with treatment‐resistant schizophrenia after recurrent violent behavior. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.12462
683. Shipton, G. (2004). Bulimia Nervosa. https://doi.org/10.1007/978-0-230-80272-8_4
684. Shirley, E. A., Hudspeth, L. J., & Maynard, J. R. (2018). Managing Sports-related Concussions From Time of Injury Through Return to Play. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-d-16-00684
685. Shirley, K. L., Norelli, L. J., & Smith, H. S. (2008). “Impulsology” <i>A New Paradigm for Addiction</i>. https://doi.org/10.1093/oso/9780195300550.003.0013
686. Shou-zh, W. (2008). Drug Psychosis by Antipsychotic Drugs:Report of 40 Cases. Zhongguo quanke yixue.
687. Shulman, M., Greiner, M., & Bisaga, A. (2023). Commentary on Foot <i>et al</i>.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder. Addiction. https://doi.org/10.1111/add.16374
688. Sidana, A., Mehta, S., & Ukey, K. (2016). Management of gambling addiction. Journal of Mental Health and Human Behaviour. https://doi.org/10.4103/0971-8990.182093
689. Siegel, S. (1988). Drug anticipation and the treatment of dependence.. PubMed.
690. Silberstein, S. D., Goadsby, P. J., & Lipton, R. B. (2000). Management of migraine: an algorithmic approach.. PubMed.
691. Silva, L. M. D., Raposo-Lima, C., Soares, C. M. G., Cerqueira, J., & Morgado, P. (2016). Koro Syndrome in an Obsessive-Compulsive Disorder Patient. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1825
692. Silva, M., Santillana, R. D. H., Martı́n, M. Á., & Fiori, E. (2025). Post traumatic stress disorder in postpartum: when guilt delays recovery. A case report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.1949
693. Silverstein, E., Basiru, T., Aulakh, M., Verzura, M. L., & Suarez, R. (2025). Management of Acute Onset Catatonia Postpartum in a Patient With a History of Major Depressive Disorder With Psychotic Features: A Case Report. Cureus. https://doi.org/10.7759/cureus.84392
694. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
695. Singh, G., Singh, H., Magny, S., Virk, I., & Gill, M. (2022). Use of Fluoxetine in Treating Compulsive Sexual Behavior: A Case Report. Cureus. https://doi.org/10.7759/cureus.29245
696. Sinha, R. (2018). Stress and Addiction. Routledge eBooks. https://doi.org/10.4324/9781315689197-25
697. Smith, P. F. (2005). The safety of cannabinoids for the treatment of multiple sclerosis. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.4.3.443
698. Smyth, D., Duffy, R. M., Flynn, D., Quirke, L., Monks, S., & Kennedy, H. (2012). DUNDRUM-D: Developmental Understanding of Drug Misuse & Dependence..
699. Smyth, J. M., Zawadzki, M. J., & Gerin, W. (2013). Stress and Disease: A Structural and Functional Analysis. Social and Personality Psychology Compass. https://doi.org/10.1111/spc3.12020
700. Snyder, S. H. (2019). CNS Stimulants And Hallucinogens. CRC Press eBooks. https://doi.org/10.1201/9780429260629-8
701. Soellner, R., & Hofheinz, C. (2017). Burden and social support in family members of relatives with problematic substance use or dementia. Suchttherapie. https://doi.org/10.1055/s-0037-1604589
702. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
703. Soulé, M., & Connery, H. S. (2017). Co-occurring Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190610999.003.0020
704. Spada, M. M., Caselli, G., & Wells, A. (2012). A Triphasic Metacognitive Formulation of Problem Drinking. Clinical Psychology & Psychotherapy. https://doi.org/10.1002/cpp.1791
705. Spencer, T. (2008). Adult ADHD: <i>Diversion and Misuse of Medications</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900003266
706. Stack, C. (2017). A Case of Spice use with Subsequent Withdrawal and Posterior Reversible Encephalopathy Syndrome (PRES) (P5.046). Neurology. https://doi.org/10.1212/wnl.88.16_supplement.p5.046
707. Stanković, M., Dostanic, N., Sarajlija, M., & Vujošević, A. (2007). Psychotic episode of multiple drug user after acute anticholinergic intoxication: A case report. Engrami.
708. Steinacker, J. M., Lehmann, M., Lormes, W., Opitz-Gress, A., Netzer, N. C., Foster, C., & Gastmann, U. (1997). Training and overtraining: an overview and experimental results in endurance sports.. PubMed.
709. Stewart, J. (2003). Stress and Relapse to Drug Seeking: Studies in Laboratory Animals Shed Light on Mechanisms and Sources of Long‐Term Vulnerability. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00535.x
710. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
711. Stone, P., Candelmi, D. E., Kandola, K., Montero, L., Smetham, D., Suleman, S., Fernando, A., & Rojí, R. (2023). Management of Fatigue in Patients with Advanced Cancer. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-022-01045-0
712. Strassnig, M., & Harvey, P. D. (2013). Treatment of obesity and disability in schizophrenia.. PubMed.
713. Stratyner, H. B. (2006). Multi-factorial Approaches to Substance Use Disorders and Addiction. CNS Spectrums. https://doi.org/10.1017/s109285290001498x
714. Streufert, S., Satish, U., Pogash, R., Gingrich, D., Landis, J. R., Lonardi, L., Miller, J., Severs, W. B., & Roache, J. D. (1996). Effects of Alprazolam on Complex Human Functioning1. Journal of Applied Social Psychology. https://doi.org/10.1111/j.1559-1816.1996.tb00105.x
715. Stringer, J. D. (2016). Gender and Sexual Health: Sexual Dysfunction.. PubMed.
716. Stubbs, B. (2011). Displays of inappropriate sexual behaviour by patients with progressive cognitive impairment: the forgotten form of challenging behaviour?. Journal of Psychiatric and Mental Health Nursing. https://doi.org/10.1111/j.1365-2850.2011.01709.x
717. Subodh, N. B., Jayarajan, D., Chand, P., Benegal, V., & Murthy, P. (2011). Lamotrigine-Induced Manic Switch. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.10l01034
718. Sullivan, M. A., & RUDNIK‐LEVIN, F. (2001). Attention Deficit/Hyperactivity Disorder and Substance Abuse. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2001.tb05783.x
719. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
720. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
721. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
722. Sussman, S. (2025). Vulnerability to addictive behaviors: the Associational Memory‐Appetitive Systems Relations Model. World Psychiatry. https://doi.org/10.1002/wps.21283
723. Sussman, S., & Ames, S. L. (2008). Concepts of Cessation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511500039.016
724. Swann, A. C. (2012). Impulsivity and Affective Regulation. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780195389715.013.0084
725. Sweet, G., Kim, S., Martin, S. A., Washington, N. B., & Brahm, N. C. (2017). Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians. Mental Health Clinician. https://doi.org/10.9740/mhc.2017.07.156
726. Szabó, P., & Szászi, B. (2021). [Body dysmorphic disorder: One Hundred Years of Solitude].. Psychiatria Hungarica.
727. Sáiz, P. A., García‐Portilla, M. P., Barrondo, S. M., Bascarán, T., García, M. B., & Bobes, J. (2003). Complicaciones psicopatológicas asociadas al consumo de drogas recreativas. Adicciones. https://doi.org/10.20882/adicciones.463
728. Sánchez-Pérez, M., Roncero, C., Gálvez-Ortiz, V., Cardoner, N., Crespo-Blanco, J. M., Navarro-Odriozola, V., García–Parés, G., Eucb, G., & Psiquiatría, S. D. (2011). Use of bubropion in elderly patients.
729. Tacn, A. (2012). PTSD in the Context of Malignant Disease. InTech eBooks. https://doi.org/10.5772/27424
730. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17-2-39
731. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17.2.39
732. Talley, N. J. (2008). Commentary: Controversies in NICE guidance on irritable bowel syndrome. BMJ. https://doi.org/10.1136/bmj.39504.409329.ad
733. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
734. Tareen, A., Garralda, M. E., & Hodes, M. (2007). Post-traumatic stress disorder in childhood. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/adc.2006.100305
735. Tatsuzawa, Y., Ono, Y., Takahashi, T., Yoshino, A., & Nomura, S. (2011). Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02207.x
736. Tedyanto, E. H., Adnyana, I. M. O., & Widyadharma, I. P. E. (2023). Tension-type Headache and Migraine as Manifestations of Chronic Post-Traumatic Headache. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v50i2.528
737. Teixeira, M. Z. (2013). Rebound effects of modern drugs: serious adverse events unknown by health professionals. Revista da Associação Médica Brasileira (English Edition). https://doi.org/10.1016/s2255-4823(13)70530-7
738. Thakur, A., Choudhary, D., Kumar, B., & Chaudhary, A. (2021). A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies. Current Molecular Pharmacology. https://doi.org/10.2174/1874467214666210525160944
739. Tharani, Z., Musaddique, A., & Qutb, S. H. (2023). Burnout and its impact on Nurses and Doctors. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.23-69
740. Thase, M. E., Salloum, I. M., & Cornelius, J. (2001). Comorbid alcoholism and depression: treatment issues.. PubMed.
741. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
742. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
743. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
744. Tollefson, G. D., Rampey, A. H., Potvin, J. H., Jenike, M. A., Rush, A. J., Dominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W. K., & Genduso, L. A. (2022). A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203822937-24
745. Tong, G., Groom, K. N., Ward, L., & Naeem, M. Y. (2021). “This Is Not the Original Timeline”: A Case Report of an Extended Dissociative Episode in a Healthy Young Male Accompanied with Severe Decline in Mental State. Case Reports in Psychiatry. https://doi.org/10.1155/2021/6619579
746. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
747. Torrens, M., Martínez-Sanvisens, D., Martinez-Riera, R., Bulbena, A., Szerman, N., & Ruiz, P. (2011). Dual Diagnosis. Addictive Disorders & Their Treatment. https://doi.org/10.1097/adt.0b013e318215f322
748. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201513040-00008
749. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2015-2058
750. Trivedi, K., Kataria, L., & Patel, D. (2020). A COMPARATIVE STUDY EVALUATING THE DEPRESSIVE SYMPTOMS AND FUNCTIONAL OUTCOME IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS V/S SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS AS ANTIDEPRESSANT AGENTS IN MAJOR DEPRESSIVE DISORDER.
751. Trujillo, K. A. (2012). The Role of NMDA Receptors in Opiate Tolerance, Sensitization, and Physical Dependence A Review of the Research, A Cellular Model, and Implications for the Treatment of Pain and Addiction.
752. Tseng, Y., Wellman, S. E., & Ho, I. (2020). Sedative-Hypnotics: Addiction and Current Research Status. Journal of Food and Drug Analysis. https://doi.org/10.38212/2224-6614.3068
753. Twenge, J. M. (2011). Generational differences in mental health: Are children and adolescents suffering more, or less?. American Journal of Orthopsychiatry. https://doi.org/10.1111/j.1939-0025.2011.01115.x
754. Tyler, R. E., & Leggio, L. (2024). Biological basis of addiction and alcohol use disorder. Clinical Liver Disease. https://doi.org/10.1097/cld.0000000000000177
755. Ungar, A. K., Konova, A. B., Patel, A. N., Goldstein, R. Z., & Hurd, Y. L. (2016). Substance Use and Addictive Disorders. https://doi.org/10.1002/9781118654231.ch16
756. Uppalapati, M., Strohl, K. P., & Sibilia, R. (2021). 854 Sexsomnia in a Divorce Proceeding and its Custody Implications. SLEEP. https://doi.org/10.1093/sleep/zsab072.851
757. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
758. Varı̀, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018). New psychoactive substances—Synthetic stimulants. Wiley Interdisciplinary Reviews Forensic Science. https://doi.org/10.1002/wfs2.1197
759. Velásquez-Martínez, M. C., & Ortíz, J. G. (2014). Abuso de Drogas: Generalidades Neurobiológicas y Terapéuticas. Actualidades en Psicología. https://doi.org/10.15517/ap.v28i117.14135
760. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
761. Vergauwen, K. (2024). Physical activity, participation and health-related quality of life in chronic fatigue syndrome and multiple osteochondromas. https://doi.org/10.26481/dis.20240425kv
762. Verhagen, E. H., Hesselmann, G. M., Besse, T. C., & Graeff, A. D. (2005). [Palliative sedation].. PubMed.
763. Verma, R., Kumar, N., & Kuppili, P. P. (2018). Repetitive Transcranial Magnetic Stimulation. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.17l02199
764. Verma, S., & Agrawal, R. (2021). The lasting effects of childhood trauma. Current psychiatry. https://doi.org/10.12788/cp.0101
765. Večeř, J., Kubátová, H., Charvát, J., Souček, M., & Kvapil, M. (2001). [Ethylene glycol poisoning].. PubMed.
766. Vicente‐Rodríguez, M., Herradón, G., & Pérez‐García, C. (2021). Toxicology of Drugs of Abuse. CRC Press eBooks. https://doi.org/10.1201/9780203730584-26
767. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
768. Vitiello, B., Zuddas, A., & Masi, G. (2006). Pharmacologic treatment of children and adolescents with attention deficit hyperactivity disorder. CRC Press eBooks. https://doi.org/10.1201/b14454-11
769. Vivanco, E. F., Gómez, C. P., & Martínez, R. G. (2006). Patología orgànica por drogas de síntesis. Adicciones.
770. Vázquez, G., Forte, A., Camino, S., Tondo, L., & Baldessarini, R. J. (2017). Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198748625.003.0017
771. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
772. Wang, S. (2001). Analysis on the 30 Cases of the Mental Barriers Caused by Taking Some Anti-psychosis Drugs. Journal of Inner Mongolia University for Nationalities.
773. Wang, S., Tang, S., Huang, J., & Chen, H. (2022). Rapid-acting antidepressants targeting modulation of the glutamatergic system: clinical and preclinical evidence and mechanisms. General Psychiatry. https://doi.org/10.1136/gpsych-2022-100922
774. Wang, Z., Wang, Y., Yue, S., Yang, F., & Singh, A. (2025). EARLY SOCIAL ISOLATION STRESS POTENTIATES HEROIN SEEKING BY AGGRAVATING THE DYSFUNCTION OF PRELIMBIC CORTEX TO VENTRAL TEGMENTAL AREA PROJECTION. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.019
775. Ward, J., Hall, K., & Haslam, C. (2006). Patterns of Memory Dysfunction in Current and 2-year Abstinent MDMA Users. Journal of Clinical and Experimental Neuropsychology. https://doi.org/10.1080/13803390490918174
776. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
777. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
778. Weller, E. B., Weller, R. A., & Dogin, J. W. (1998). A rose is a rose is a rose. Journal of Affective Disorders. https://doi.org/10.1016/s0165-0327(98)00180-3
779. Wenbing, C., Asano, T., Notaka, I., Shin-Ichi, M., & Nitta, A. (2025). SUPPRESSION OF TENEURIN-4 IN THE NUCLEUS ACCUMBENS ALLEVIATES METHAMPHETAMINE-INDUCED DOPAMINE RELEASE AND BEHAVIORAL ALTERATIONS IN MICE. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.174
780. White, C. M. (2014). How MDMA's Pharmacology and Pharmacokinetics Drive Desired Effects and Harms. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.266
781. Wick, J. Y., & Zanni, G. R. (2011). Helping Those with Hoarding Behaviors. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2011.458
782. Wieser, T., Walliser, U., Womastek, I., & Kress, H. G. (2011). Dysfunctional coping in headache: Avoidance and endurance is not associated with chronic forms of headache. European Journal of Pain. https://doi.org/10.1016/j.ejpain.2011.06.011
783. Williams, R. H., & Erickson, T. B. (2000). Evaluating Hallucinogenic or Psychedelic Drug Intoxication in an Emergency Setting. Laboratory Medicine. https://doi.org/10.1309/v3j8-3kw2-bpt1-fu15
784. Winbigler, B. L., & Chyka, P. A. (2022). Chapter 43: Substance Misuse and Toxicology. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123615.ch43
785. Winstock, A., & Flechais, R. (2020). Stimulants, ecstasy, and other ‘party drugs’. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0053
786. Winstock, A., & Schifano, F. (2012). Disorders relating to the use of ecstasy and other ‘party drugs’. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0066
787. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
788. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
789. Wise, E., Lyketsos, C. G., & Onyike, C. U. (2018). Aggression and Violence. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl06
790. Wissow, L. S. (2021). Anxiety and Trauma-Related Distress. Pediatric Care Online. https://doi.org/10.1542/aap.ppcqr.396464
791. Wolf, M. E. (2002). Addiction and Glutamate-Dependent Plasticity. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_8
792. Wolff, A., Vanduynhoven, E., Kleef, M. V., Huygen, F., Pope, J. E., & Mekhail, N. (2011). 21. Phantom Pain. Pain Practice. https://doi.org/10.1111/j.1533-2500.2011.00454.x
793. Wolkoff, D. A. (1997). Methamphetamine abuse: an overview for health care professionals.. PubMed.
794. Wong, M. K., Darvishzadeh, A., Maler, N. A., & Bota, R. G. (2016). Five Supplements and Multiple Psychotic Symptoms: A Case Report. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.15br01856
795. Włodarczyk, A., Cubała, W. J., Szarmach, J., Małyszko, A., & Wiglusz, M. S. (2019). Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system.. PubMed.
796. Yan, C., Taneja, K., & Tang, S. (2023). Obsessive compulsive disorder due to dexamethasone use. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100123
797. Yang, B.-K., Yi, S.-R., Ahn, Y.-J., Im, S. H., & Park, S. H. (2016). Ischial Tuberosity Avulsion Stress Fracture after Short Period of Repetitive Training. Hip & Pelvis. https://doi.org/10.5371/hp.2016.28.3.187
798. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
799. Yetkın, S., & Çor, S. A. (2023). Psychological Inflexibility in Depression with Psychotic Features: A Case Report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2180
800. Yonkers, K. A. (2004). Panic and Agoraphobia: Gender as a Factor. CNS Spectrums. https://doi.org/10.1017/s1092852900001991
801. Young, A. H., Macritchie, K., & Calabrese, J. R. (2000). Treatment of bipolar affective disorder. BMJ. https://doi.org/10.1136/bmj.321.7272.1302
802. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
803. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
804. Zhang, H. (2010). Therapeutic effectiveness and patient acceptance of a vestibular nerve activation intervention in chronic insomnia.
805. Zhang, Z., Greenberg, A. S., Rose, L., Jayasooriya, T., Thomas, N., & Das, S. (2025). A case of depression with psychotic features associated with hemoglobin Manukau mutation. Psychiatry and Clinical Neurosciences Reports. https://doi.org/10.1002/pcn5.70145
806. Zheng, J.-W., Meng, S., Liu, W.-Y., Chang, X., & Shi, J. (2023). [Appropriate Use and Abuse of Sedative-Hypnotic Drugs].. PubMed. https://doi.org/10.12182/20230260302
807. Zillmer, E. A., Montenegro, L. M., Wiser, J., Barth, J. T., & Spyker, D. A. (1996). Neuropsychological sequelae in subacute home chlordane poisoning: Ten case studies. Archives of Clinical Neuropsychology. https://doi.org/10.1093/arclin/11.1.77
808. Zoellner, L. A., Graham, B., & Bedard‐Gilligan, M. (2019). Trauma- and Stressor-Related Disorders. Routledge eBooks. https://doi.org/10.4324/9780429028267-10
809. Zschucke, E., Gaudlitz, K., & Ströhle, A. (2013). Exercise and Physical Activity in Mental Disorders: Clinical and Experimental Evidence. Journal of Preventive Medicine and Public Health. https://doi.org/10.3961/jpmph.2013.46.s.s12
810. Zulkifli, N., Khuzaini, A. M., Aziz, A. A., & Awang, H. (2023). Trauma-related hallucination in an 8-year-old child with dissociative symptoms. Deleted Journal. https://doi.org/10.4103/mjp.mjp_10_23
811. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
812. ŚWIĘCICKA, N. (2018). Compulsive behavior in fur animals. Medycyna Weterynaryjna. https://doi.org/10.21521/mw.5999
813. Šibor, J., Holý, L., & Rezáková, O. (2005). RÁMCOVÝ (ŠKOLNÍ) VZDĚLÁVACÍ PROGRAM VE VZTAHU K DUŠEVNÍM ABEHAVIORÁLNÍM PORUCHÁMSTRES.
814. Ștefănescu, C., Chiriță, R., Chiriţă, V., & Chele, G. (2009). The Comorbidity of Depression and Substance Abuse Disorders in Romanian Patients. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)70858-2